<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144393</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-558X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuroreport</Title>
                <ISOAbbreviation>Neuroreport</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dynamics of sodium channel Nav1.5 expression in astrocytes in mouse models of multiple sclerosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Astrocytes actively participate in the response of the central nervous system to injury, including in multiple sclerosis. Astrocytes can play both beneficial and detrimental roles in response to neuroinflammation; however, in extreme cases, astrogliosis can result in the formation of a glial scar, which can impede the regeneration of injured neurons. Although astrocytes do not express the voltage-gated sodium channel Nav1.5 in the nonpathological human brain, they exhibit robust upregulation of Nav1.5 within acute and chronic multiple sclerosis lesions. Recent work has indicated that Nav1.5 contributes to the pathways that regulate glial scar formation in vitro through modulation of intracellular Ca levels. However, the temporal dynamics of astrocytic Nav1.5 channel expression in response to neuroinflammatory pathologies has not been investigated. We examined astrocytes from mice with monophasic and chronic-relapsing (CR) experimental autoimmune encephalomyelitis (EAE) by immunohistochemical analysis to determine whether Nav1.5 is expressed in these cells, and whether the expression correlates with the severity of disease and/or phases of relapse and remission. Our results demonstrate that Nav1.5 is upregulated in astrocytes in situ in a temporal manner that correlates with disease severity in both monophasic and CR EAE. Further, in CR EAE, Nav1.5 expression is upregulated during relapses and subsequently attenuated during periods of remission. These observations are consistent with the suggestion that Nav1.5 can play a role in the response of astrocytes to inflammatory pathologies in the central nervous system and suggest Nav1.5 may be a potential therapeutic target to modulate reactive astrogliosis in vivo.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Pappalardo</LastName>
                    <ForeName>Laura W</ForeName>
                    <Initials>LW</Initials>
                    <Affiliation>aDepartment of Neurology, Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven bRehabilitation Research Center, VA Connecticut Healthcare System, West Haven, Connecticut, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Shujun</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Black</LastName>
                    <ForeName>Joel A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author>
                    <LastName>Waxman</LastName>
                    <ForeName>Stephen G</ForeName>
                    <Initials>SG</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neuroreport</MedlineTA>
            <NlmUniqueID>9100935</NlmUniqueID>
            <ISSNLinking>0959-4965</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNR.0000000000000249</ArticleId>
            <ArticleId IdType="pubmed">25144393</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144390</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High susceptibility to fatty liver disease in two-pore channel 2-deficient mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4699</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms5699</ELocationID>
            <Abstract>
                <AbstractText>Endolysosomal organelles play a key role in trafficking, breakdown and receptor-mediated recycling of different macromolecules such as low-density lipoprotein (LDL)-cholesterol, epithelial growth factor (EGF) or transferrin. Here we examine the role of two-pore channel (TPC) 2, an endolysosomal cation channel, in these processes. Embryonic mouse fibroblasts and hepatocytes lacking TPC2 display a profound impairment of LDL-cholesterol and EGF/EGF-receptor trafficking. Mechanistically, both defects can be attributed to a dysfunction of the endolysosomal degradation pathway most likely on the level of late endosome to lysosome fusion. Importantly, endolysosomal acidification or lysosomal enzyme function are normal in TPC2-deficient cells. TPC2-deficient mice are highly susceptible to hepatic cholesterol overload and liver damage consistent with non-alcoholic fatty liver hepatitis. These findings indicate reduced metabolic reserve of hepatic cholesterol handling. Our results suggest that TPC2 plays a crucial role in trafficking in the endolysosomal degradation pathway and, thus, is potentially involved in the homoeostatic control of many macromolecules and cell metabolites.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Grimm</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holdt</LastName>
                    <ForeName>Lesca M</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>1] Institute of Laboratory Medicine-University Hospital Munich, 81377 Munich, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Cheng-Chang</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>1] Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassan</LastName>
                    <ForeName>Sami</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>M??ller</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy, Ludwig-Maximilians-Universit??t M??nchen, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>J??rs</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>2nd Department of Internal Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cuny</LastName>
                    <ForeName>Hartmut</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1] Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany [2] [3].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kissing</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit??t Kiel, 24118 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schr??der</LastName>
                    <ForeName>Bernd</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit??t Kiel, 24118 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Butz</LastName>
                    <ForeName>Elisabeth</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Northoff</LastName>
                    <ForeName>Bernd</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Laboratory Medicine-University Hospital Munich, 81377 Munich, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castonguay</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-Universit??t Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luber</LastName>
                    <ForeName>Christian A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>1] Max-Planck-Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moser</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Max-Planck-Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spahn</LastName>
                    <ForeName>Saskia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>L??llmann-Rauch</LastName>
                    <ForeName>Renate</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institute of Anatomy, Christian-Albrechts-Universit??t Kiel, 24098 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fendel</LastName>
                    <ForeName>Christina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institute for Cell Biology, Rheinische Friedrich-Wilhelms-Universit??t Bonn, 53121 Bonn, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klugbauer</LastName>
                    <ForeName>Norbert</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-Universit??t Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Griesbeck</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Max-Planck-Institute of Neurobiology, Am Klopferspitz 18, 82152 Martinsried, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haas</LastName>
                    <ForeName>Albert</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute for Cell Biology, Rheinische Friedrich-Wilhelms-Universit??t Bonn, 53121 Bonn, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mann</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Max-Planck-Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bracher</LastName>
                    <ForeName>Franz</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Pharmacy, Ludwig-Maximilians-Universit??t M??nchen, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teupser</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Institute of Laboratory Medicine-University Hospital Munich, 81377 Munich, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saftig</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit??t Kiel, 24118 Kiel, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biel</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl-Schott</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universit??t, 81377 M??nchen, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ncomms5699</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms5699</ArticleId>
            <ArticleId IdType="pubmed">25144390</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144366</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1553-7374</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS pathogens</Title>
                <ISOAbbreviation>PLoS Pathog.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ly6Chi Monocyte Recruitment Is Responsible for Th2 Associated Host-Protective Macrophage Accumulation in Liver Inflammation due to Schistosomiasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1004282</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1004282</ELocationID>
            <Abstract>
                <AbstractText>Accumulation of M2 macrophages in the liver, within the context of a strong Th2 response, is a hallmark of infection with the parasitic helminth, Schistosoma mansoni, but the origin of these cells is unclear. To explore this, we examined the relatedness of macrophages to monocytes in this setting. Our data show that both monocyte-derived and resident macrophages are engaged in the response to infection. Infection caused CCR2-dependent increases in numbers of Ly6Chi monocytes in blood and liver and of CX3CR1+ macrophages in diseased liver. Ly6Chi monocytes recovered from liver had the potential to differentiate into macrophages when cultured with M-CSF. Using pulse chase BrdU labeling, we found that most hepatic macrophages in infected mice arose from monocytes. Consistent with this, deletion of monocytes led to the loss of a subpopulation of hepatic CD11chi macrophages that was present in infected but not na??ve mice. This was accompanied by a reduction in the size of egg-associated granulomas and significantly exacerbated disease. In addition to the involvement of monocytes and monocyte-derived macrophages in hepatic inflammation due to infection, we observed increased incorporation of BrdU and expression of Ki67 and MHC II in resident macrophages, indicating that these cells are participating in the response. Expression of both M2 and M1 marker genes was increased in liver from infected vs. naive mice. The M2 fingerprint in the liver was not accounted for by a single cell type, but rather reflected expression of M2 genes by various cells including macrophages, neutrophils, eosinophils and monocytes. Our data point to monocyte recruitment as the dominant process for increasing macrophage cell numbers in the liver during schistosomiasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nascimento</LastName>
                    <ForeName>Marcia</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Stanley C</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Amber</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Everts</LastName>
                    <ForeName>Bart</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lam</LastName>
                    <ForeName>Wing</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bassity</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Trudeau Institute, Saranac Lake, New York, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gautier</LastName>
                    <ForeName>Emmanuel L</ForeName>
                    <Initials>EL</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Randolph</LastName>
                    <ForeName>Gwendalyn J</ForeName>
                    <Initials>GJ</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pearce</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Pathog</MedlineTA>
            <NlmUniqueID>101238921</NlmUniqueID>
            <ISSNLinking>1553-7366</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1004282</ArticleId>
            <ArticleId IdType="pii">PPATHOGENS-D-13-02087</ArticleId>
            <ArticleId IdType="pubmed">25144366</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144359</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1553-7358</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS computational biology</Title>
                <ISOAbbreviation>PLoS Comput. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tracing the evolution of lineage-specific transcription factor binding sites in a birth-death framework.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1003771</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pcbi.1003771</ELocationID>
            <Abstract>
                <AbstractText>Changes in cis-regulatory element composition that result in novel patterns of gene expression are thought to be a major contributor to the evolution of lineage-specific traits. Although transcription factor binding events show substantial variation across species, most computational approaches to study regulatory elements focus primarily upon highly conserved sites, and rely heavily upon multiple sequence alignments. However, sequence conservation based approaches have limited ability to detect lineage-specific elements that could contribute to species-specific traits. In this paper, we describe a novel framework that utilizes a birth-death model to trace the evolution of lineage-specific binding sites without relying on detailed base-by-base cross-species alignments. Our model was applied to analyze the evolution of binding sites based on the ChIP-seq data for six transcription factors (GATA1, SOX2, CTCF, MYC, MAX, ETS1) along the lineage toward human after human-mouse common ancestor. We estimate that a substantial fraction of binding sites (???58-79% for each factor) in humans have origins since the divergence with mouse. Over 15% of all binding sites are unique to hominids. Such elements are often enriched near genes associated with specific pathways, and harbor more common SNPs than older binding sites in the human genome. These results support the ability of our method to identify lineage-specific regulatory elements and help understand their roles in shaping variation in gene regulation across species.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yokoyama</LastName>
                    <ForeName>Ken Daigoro</ForeName>
                    <Initials>KD</Initials>
                    <Affiliation>Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America; Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Comput Biol</MedlineTA>
            <NlmUniqueID>101238922</NlmUniqueID>
            <ISSNLinking>1553-734X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pcbi.1003771</ArticleId>
            <ArticleId IdType="pii">PCOMPBIOL-D-14-00701</ArticleId>
            <ArticleId IdType="pubmed">25144359</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144323</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cardiac arrhythmia induced by genetic silencing of 'funny' (f) channels is rescued by GIRK4 inactivation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4664</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms5664</ELocationID>
            <Abstract>
                <AbstractText>The mechanisms underlying cardiac automaticity are still incompletely understood and controversial. Here we report the complete conditional and time-controlled silencing of the 'funny' current (If) by expression of a dominant-negative, non-conductive HCN4-channel subunit (hHCN4-AYA). Heart-specific If silencing caused altered [Ca(2+)]i release and Ca(2+) handling in the sinoatrial node, impaired pacemaker activity and symptoms reminiscent of severe human disease of pacemaking. The effects of If silencing critically depended on the activity of the autonomic nervous system. We were able to rescue the failure of impulse generation and conduction by additional genetic deletion of cardiac muscarinic G-protein-activated (GIRK4) channels in If-deficient mice without impairing heartbeat regulation. Our study establishes the role of f-channels in cardiac automaticity and indicates that arrhythmia related to HCN loss-of-function may be managed by pharmacological or genetic inhibition of GIRK4 channels, thus offering a new therapeutic strategy for the treatment of heart rhythm diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mesirca</LastName>
                    <ForeName>Pietro</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alig</LastName>
                    <ForeName>Jacqueline</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Experimental Neuropediatrics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torrente</LastName>
                    <ForeName>Angelo G</ForeName>
                    <Initials>AG</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>M??ller</LastName>
                    <ForeName>Jana Christina</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Department of Cellular and Integrative Physiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marger</LastName>
                    <ForeName>Laurine</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rollin</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marquilly</LastName>
                    <ForeName>Claire</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vincent</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dubel</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bidaud</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fernandez</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Centre national de la recherche scientifique, UPR-1142, Institut de G??n??tique Humaine, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seniuk</LastName>
                    <ForeName>Anika</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] Department of Cellular and Integrative Physiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), University Medical Center Hamburg-Eppendorf, partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Engeland</LastName>
                    <ForeName>Birgit</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>1] Experimental Neuropediatrics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Experimental Neurophysiology, University Hospital Cologne, 50924 Cologne, Germany [3] German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Jasmin</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Experimental Pharmacology and Toxicology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miquerol</LastName>
                    <ForeName>Lucile</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Developmental Biology Institute of Marseille, Universit?? Aix-Marseille, CNRS UMR 7288, 13288 Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ehmke</LastName>
                    <ForeName>Heimo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1] Department of Cellular and Integrative Physiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), University Medical Center Hamburg-Eppendorf, partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eschenhagen</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>1] Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), University Medical Center Hamburg-Eppendorf, partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany [2] Department of Experimental Pharmacology and Toxicology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nargeot</LastName>
                    <ForeName>Joel</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wickman</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Isbrandt</LastName>
                    <ForeName>Dirk</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>1] Experimental Neuropediatrics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany [2] Experimental Neurophysiology, University Hospital Cologne, 50924 Cologne, Germany [3] German Center for Neurodegenerative Diseases (DZNE), 53175, Bonn, Germany [4].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mangoni</LastName>
                    <ForeName>Matteo E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>1] D??partement de Physiologie, Institut de G??nomique Fonctionnelle, LabEx ICST, F-34094 Montpellier, France [2] UMR-5203, Centre national de la recherche scientifique, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [3] INSERM U661, Universit??s de Montpellier 1 &amp;2, F-34094 Montpellier, France [4].</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ncomms5664</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms5664</ArticleId>
            <ArticleId IdType="pubmed">25144323</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144316</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-7422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human gene therapy</Title>
                <ISOAbbreviation>Hum. Gene Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>&lt;i&gt;In vivo&lt;/i&gt; evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Patients with cystic fibrosis (CF) often suffer chronic lung infection with concomitant inflammation, a setting that may reduce the efficacy of gene transfer. While gene therapy development for CF often involves viral-based vectors, little is known about gene transfer in the context of an infected airway. In this study, three mouse models were established to evaluate adeno-associated virus (AAV) gene transfer in such an environment. &lt;i&gt;Bordetella bronchiseptica&lt;/i&gt; RB50 was used in a chronic, non-lethal respiratory infection in C57BL/6 mice. An inoculum of ~10&lt;sup&gt;5&lt;/sup&gt; CFU allowed &lt;i&gt;B.bronchiseptica&lt;/i&gt; RB50 to persist in the upper and lower respiratory tracts for at least 21 days. In this infection model administration of an AAV vector on day 2 resulted in an approximately three-fold reduction of reporter gene expression compared to that observed in uninfected controls. Postponement of AAV administration to day 14 resulted in an even greater (eight-fold) reduction of reporter gene expression, when compared to uninfected controls. In another infection model, &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; PAO1 was used to infect surfactant protein D (SP-D) or surfactant protein A (SP-A) knockout (KO) mice. With an inoculum of ~10&lt;sup&gt;5&lt;/sup&gt; CFU, infection persisted for two days in the nasal cavity of either mouse model. Reporter gene expression was approximately ~2.5 fold lower compared to uninfected mice. In the SP-D KO model, postponement of AAV administration to day 9 post-infection resulted in only a 2-fold reduction in reporter gene expression, when compared to expression seen in uninfected controls. These results confirm that respiratory infections, both on-going and recently resolved, decrease the efficacy of AAV-mediated gene transfer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Myint</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Pennsylvania, Institute for Medicine and Engineering, Department of Chemical &amp; Biomolecular Engineering, Philadelphia, Pennsylvania, United States ; mmyint@seas.upenn.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Limberis</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Bell</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Somanathan</LastName>
                    <ForeName>Suryanarayan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Haczku</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Wilson</LastName>
                    <ForeName>James M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author>
                    <LastName>Diamond</LastName>
                    <ForeName>Scott L</ForeName>
                    <Initials>SL</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hum Gene Ther</MedlineTA>
            <NlmUniqueID>9008950</NlmUniqueID>
            <ISSNLinking>1043-0342</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2014.002</ArticleId>
            <ArticleId IdType="pubmed">25144316</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144310</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Assessment of mouse germinal vesicle stage oocyte quality by evaluating the cumulus layer, zona pellucida, and perivitelline space.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105812</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105812</ELocationID>
            <Abstract>
                <AbstractText>To improve the outcome of assisted reproductive technology (ART) for patients with ovulation problems, it is necessary to retrieve and select germinal vesicle (GV) stage oocytes with high developmental potential. Oocytes with high developmental potential are characterized by their ability to undergo proper maturation, fertilization, and embryo development. In this study, we analyzed morphological traits of GV stage mouse oocytes, including cumulus cell layer thickness, zona pellucida thickness, and perivitelline space width. Then, we assessed the corresponding developmental potential of each of these oocytes and found that it varies across the range measured for each morphological trait. Furthermore, by manipulating these morphological traits in vitro, we were able to determine the influence of morphological variation on oocyte developmental potential. Manually altering the thickness of the cumulus layer showed strong effects on the fertilization and embryo development potentials of oocytes, whereas manipulation of zona pellucida thickness effected the oocyte maturation potential. Our results provide a systematic detailed method for selecting GV stage oocytes based on a morphological assessment approach that would benefit for several downstream ART applications.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Hong-Xia</ForeName>
                    <Initials>HX</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Yu-Zhen</ForeName>
                    <Initials>YZ</Initials>
                    <Affiliation>Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ying-Lei</ForeName>
                    <Initials>YL</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Cheng-Jie</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Sha-Na</ForeName>
                    <Initials>SN</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Jiang-Peng</ForeName>
                    <Initials>JP</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Cheng-Guang</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>The Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University, Hohhot, Inner Mongolia, People's Republic of China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105812</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-28075</ArticleId>
            <ArticleId IdType="pubmed">25144310</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144301</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hyperglycemia Promotes K-Ras-Induced Lung Tumorigenesis through BASCs Amplification.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105550</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105550</ELocationID>
            <Abstract>
                <AbstractText>Oncogenic K-Ras represents the most common molecular change in human lung adenocarcinomas, the major histologic subtype of non-small cell lung cancer (NSCLC). The presence of K-Ras mutation is associated with a poor prognosis, but no effective treatment strategies are available for K-Ras -mutant NSCLC. Epidemiological studies report higher lung cancer mortality rates in patients with type 2 diabetes. Here, we use a mouse model of K-Ras-mediated lung cancer on a background of chronic hyperglycemia to determine whether elevated circulating glycemic levels could influence oncogenic K-Ras-mediated tumor development. Inducible oncogenic K-Ras mouse model was treated with subtoxic doses of streptozotocin (STZ) to induce chronic hyperglycemia. We observed increased tumor mass and higher grade of malignancy in STZ treated diabetic mice analyzed at 4, 12 and 24 weeks, suggesting that oncogenic K-Ras increased lung tumorigenesis in hyperglycemic condition. This promoting effect is achieved by expansion of tumor-initiating lung bronchio-alveolar stem cells (BASCs) in bronchio-alveolar duct junction, indicating a role of hyperglycemia in the activity of K-Ras-transformed putative lung stem cells. Notably, after oncogene K-Ras activation, BASCs show upregulation of the glucose transporter (Glut1/Slc2a1), considered as an important player of the active control of tumor cell metabolism by oncogenic K-Ras. Our novel findings suggest that anti-hyperglycemic drugs, such as metformin, may act as therapeutic agent to restrict lung neoplasia promotion and progression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Micucci</LastName>
                    <ForeName>Carla</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Clinical and Molecular Sciences, Polytechnic University of Marche, School of Medicine, Ancona, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Orciari</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Clinical and Molecular Sciences, Polytechnic University of Marche, School of Medicine, Ancona, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Catalano</LastName>
                    <ForeName>Alfonso</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Clinical and Molecular Sciences, Polytechnic University of Marche, School of Medicine, Ancona, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105550</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-14371</ArticleId>
            <ArticleId IdType="pubmed">25144301</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144240</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-8534</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Stem cells and development</Title>
                <ISOAbbreviation>Stem Cells Dev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Stress-Induced Enzyme Activation Primes Murine Embryonic Stem Cells to Differentiate toward the First Extraembryonic Lineage.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Extracellular stresses influence transcription factor (TF) expression and therefore lineage identity in the peri-implantation mouse embryo and its stem cells. This potentially affects pregnancy outcome. To understand the effects of stress signaling during this critical period of pregnancy, we exposed cultured murine embryonic stem cells (mESCs) to hyperosmotic stress. We then measured stress enzyme-dependent regulation of key pluripotency and lineage TFs. Hyperosmotic stress slowed mESC accumulation due to slowing of the cell cycle over 72hr, after a small apoptotic response within 12hr. PI3K enzymatic signaling was responsible for stem cell survival under stressed conditions. Stress initially triggered mESC differentiation after 4hr through MEK1, JNK, and PI3K enzymatic signaling, which led to proteasomal degradation of Oct4, Nanog, Sox2, and Rex1 TF proteins. Concurrent with this post-transcriptional effect was the decreased accumulation of potency TF mRNA transcripts. After 12-24hr of stress, cells adapted, cell cycle resumed, and Oct4 and Nanog mRNA and protein expression returned to ~normal levels. The TF protein recovery was mediated by p38MAPK and PI3K signaling, as well as by MEK2 and/or 1. However, due to JNK signaling Rex1 expression did not recover. Probing for downstream lineages revealed that although mESCs did not differentiate morphologically during 24hr of stress, they were primed to differentiate by upregulating markers of the first lineage differentiating from mESCs; extraembryonic endoderm. Thus, although 2-3 TFs which mark pluripotency recover expression by 24hr of stress, there is nonetheless sustained Rex1 suppression and a priming of mESCs for differentiation to the earliest lineage.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Slater</LastName>
                    <ForeName>Jill Drappole Med Wayne Edu</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Wayne State University, Physiology, detroit, Michigan, United States ; jislater@umflint.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Sichang Drappole Med Wayne Edu</ForeName>
                    <Initials>SD</Initials>
                </Author>
                <Author>
                    <LastName>Puscheck</LastName>
                    <ForeName>Elizabeth Ella</ForeName>
                    <Initials>EE</Initials>
                </Author>
                <Author>
                    <LastName>Rappolee</LastName>
                    <ForeName>Daniel A</ForeName>
                    <Initials>DA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Stem Cells Dev</MedlineTA>
            <NlmUniqueID>101197107</NlmUniqueID>
            <ISSNLinking>1547-3287</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/scd.2014.0157</ArticleId>
            <ArticleId IdType="pubmed">25144240</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144231</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of machado-joseph disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e100086</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0100086</ELocationID>
            <Abstract>
                <AbstractText>Machado-Joseph disease or Spinocerebellar ataxia type 3 is a progressive fatal neurodegenerative disorder caused by the polyglutamine-expanded protein ataxin-3. Recent studies demonstrate that RNA interference is a promising approach for the treatment of Machado-Joseph disease. However, whether gene silencing at an early time-point is able to prevent the appearance of motor behavior deficits typical of the disease when initiated before onset of the disease had not been explored. Here, using a lentiviral-mediated allele-specific silencing of mutant ataxin-3 in an early pre-symptomatic cerebellar mouse model of Machado-Joseph disease we show that this strategy hampers the development of the motor and neuropathological phenotypic characteristics of the disease. At the histological level, the RNA-specific silencing of mutant ataxin-3 decreased formation of mutant ataxin-3 aggregates, preserved Purkinje cell morphology and expression of neuronal markers while reducing cell death. Importantly, gene silencing prevented the development of impairments in balance, motor coordination, gait and hyperactivity observed in control mice. These data support the therapeutic potential of RNA interference for Machado-Joseph disease and constitute a proof of principle of the beneficial effects of early allele-specific silencing for therapy of this disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>N??brega</LastName>
                    <ForeName>Cl??vio</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nascimento-Ferreira</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Onofre</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Albuquerque</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D??glon</LastName>
                    <ForeName>Nicole</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Lausanne University Hospital, Department of Clinical Neurosciences, Laboratory of Cellular and Molecular Neurotherapies, Lausanne, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pereira de Almeida</LastName>
                    <ForeName>Lu??s</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>CNC - Center for Neuroscience &amp; Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0100086</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-47238</ArticleId>
            <ArticleId IdType="pubmed">25144231</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144228</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1553-7374</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS pathogens</Title>
                <ISOAbbreviation>PLoS Pathog.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Late Engagement of CD86 after Influenza Virus Clearance Promotes Recovery in a FoxP3+ Regulatory T Cell Dependent Manner.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1004315</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1004315</ELocationID>
            <Abstract>
                <AbstractText>Influenza A virus (IAV) infection in the respiratory tract triggers robust innate and adaptive immune responses, resulting in both virus clearance and lung inflammation and injury. After virus clearance, resolution of ongoing inflammation and tissue repair occur during a distinct recovery period. B7 family co-stimulatory molecules such as CD80 and CD86 have important roles in modulating T cell activity during the initiation and effector stages of the host response to IAV infection, but their potential role during recovery and resolution of inflammation is unknown. We found that antibody-mediated CD86 blockade in vivo after virus clearance led to a delay in recovery, characterized by increased numbers of lung neutrophils and inflammatory cytokines in airways and lung interstitium, but no change in conventional IAV-specific T cell responses. However, CD86 blockade led to decreased numbers of FoxP3+ regulatory T cells (Tregs), and adoptive transfer of Tregs into ??CD86 treated mice rescued the effect of the blockade, supporting a role for Tregs in promoting recovery after virus clearance. Specific depletion of Tregs late after infection mimicked the CD86 blockade phenotype, confirming a role for Tregs during recovery after virus clearance. Furthermore, we identified neutrophils as a target of Treg suppression since neutrophil depletion in Treg-depleted mice reduced excess inflammatory cytokines in the airways. These results demonstrate that Tregs, in a CD86 dependent mechanism, contribute to the resolution of disease after IAV infection, in part by suppressing neutrophil-driven cytokine release into the airways.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moser</LastName>
                    <ForeName>Emily K</ForeName>
                    <Initials>EK</Initials>
                    <Affiliation>The Beirne B. Carter Center for Immunology Research, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Pharmacology, The University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hufford</LastName>
                    <ForeName>Matthew M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>The Beirne B. Carter Center for Immunology Research, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Microbiology, The University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braciale</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>The Beirne B. Carter Center for Immunology Research, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Microbiology, The University of Virginia, Charlottesville, Virginia, United States of America; Department of Pathology, The University of Virginia, Charlottesville, Virginia, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Pathog</MedlineTA>
            <NlmUniqueID>101238921</NlmUniqueID>
            <ISSNLinking>1553-7366</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1004315</ArticleId>
            <ArticleId IdType="pii">PPATHOGENS-D-14-00685</ArticleId>
            <ArticleId IdType="pubmed">25144228</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144225</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1935-2735</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS neglected tropical diseases</Title>
                <ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Effect of (-)-Epigallocatechin 3-O - Gallate In Vitro and In Vivo in Leishmania braziliensis: Involvement of Reactive Oxygen Species as a Mechanism of Action.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e3093</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0003093</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Leishmaniasis is a parasitic disease associated with extensive mortality and morbidity. The treatment for leishmaniasis is currently based on pentavalent antimonials and amphotericin B; however, these drugs result in numerous adverse side effects. Natural compounds have been used as novel treatments for parasitic diseases. In this paper, we evaluated the effect of (-)-epigallocatechin 3-O-gallate (EGCG) on Leishmania braziliensis in vitro and in vivo and described the mechanism of EGCG action against L. braziliensis promastigotes and intracellular amastigotes.</AbstractText>
                <AbstractText Label="METHODOLOGY/PRINCIPAL FINDING" NlmCategory="RESULTS">In vitro activity and reactive oxygen species (ROS) measurements were determined during the promastigote and intracellular amastigote life stages. The effect of EGCG on mitochondrial membrane potential (????m) was assayed using JC-1, and intracellular ATP concentrations were measured using a luciferin-luciferase system. The in vivo experiments were performed in infected BALB/c mice orally treated with EGCG. EGCG reduced promastigote viability and the infection index in a time- and dose-dependent manner, with IC50 values of 278.8 ??M and 3.4 ??M, respectively, at 72 h and a selectivity index of 149.5. In addition, EGCG induced ROS production in the promastigote and intracellular amastigote, and the effects were reversed by polyethylene glycol (PEG)-catalase. Additionally, EGCG reduced ????m, thereby decreasing intracellular ATP concentrations in promastigotes. Furthermore, EGCG treatment was also effective in vivo, demonstrating oral bioavailability and reduced parasitic loads without altering serological toxicity markers.</AbstractText>
                <AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">In conclusion, our study demonstrates the leishmanicidal effects of EGCG against the two forms of L. braziliensis, the promastigote and amastigote. In addition, EGCG promotes ROS production as a part of its mechanism of action, resulting in decreased ????m and reduced intracellular ATP concentrations. These actions ultimately culminate in parasite death. Furthermore, our data suggest that EGCG is orally effective in the treatment of L. braziliensis-infected BALB/c mice without altering serological toxicity markers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Inacio</LastName>
                    <ForeName>Job D F</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gervazoni</LastName>
                    <ForeName>Luiza</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Canto-Cavalheiro</LastName>
                    <ForeName>Marilene M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Almeida-Amaral</LastName>
                    <ForeName>Elmo E</ForeName>
                    <Initials>EE</Initials>
                    <Affiliation>Laborat??rio de Bioqu??mica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Funda????o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Negl Trop Dis</MedlineTA>
            <NlmUniqueID>101291488</NlmUniqueID>
            <ISSNLinking>1935-2727</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0003093</ArticleId>
            <ArticleId IdType="pii">PNTD-D-14-00554</ArticleId>
            <ArticleId IdType="pubmed">25144225</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144208</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Trans-regulation of oligodendrocyte myelination by neurons through small GTPase Arf6-regulated secretion of fibroblast growth factor-2.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4744</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms5744</ELocationID>
            <Abstract>
                <AbstractText>The small G protein ADP-ribosylation factor 6 (Arf6) plays important roles in a wide variety of membrane dynamics-based cellular events such as neurite outgrowth and spine formation in vitro. However, little is known about physiological function of Arf6 in vivo. Here we generate conditional knockout mice lacking Arf6 in neurons, oligodendrocytes, or both cell lineages, and unexpectedly find that Arf6 expression in neurons, but not in oligodendrocytes, is crucial for oligodendrocyte myelination in the hippocampal fimbria and the corpus callosum during development, and that this is through the regulation of secretion of fibroblast growth factor-2, a guidance factor for migration of oligodendrocyte precursor cells (OPCs). These results suggest that Arf6 in neurons plays an important role in OPC migration through regulation of FGF-2 secretion during neuronal development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Akiyama</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>1] Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasegawa</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1] Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hongu</LastName>
                    <ForeName>Tsunaki</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>1] Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan [2].</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frohman</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Department of Pharmacology, Center for Developmental Genetics, Stony Brook University, Stony Brook, New York 11794-5140, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harada</LastName>
                    <ForeName>Akihiro</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Cell Biology, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakagami</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0329, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanaho</LastName>
                    <ForeName>Yasunori</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Faculty of Medicine, Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ncomms5744</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms5744</ArticleId>
            <ArticleId IdType="pubmed">25144208</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25144196</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ezrin Mediates Neuritogenesis via Down-Regulation of RhoA Activity in Cultured Cortical Neurons.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105435</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105435</ELocationID>
            <Abstract>
                <AbstractText>Neuronal morphogenesis is implicated in neuronal function and development with rearrangement of cytoskeletal organization. Ezrin, a member of Ezrin/Radixin/Moesin (ERM) proteins links between membrane proteins and actin cytoskeleton, and contributes to maintenance of cellular function and morphology. In cultured hippocampal neurons, suppression of both radixin and moesin showed deficits in growth cone morphology and neurite extensions. Down-regulation of ezrin using siRNA caused impairment of netrin-1-induced axon outgrowth in cultured cortical neurons. However, roles of ezrin in the neuronal morphogenesis of the cultured neurons have been poorly understood. In this report, we performed detailed studies on the roles of ezrin in the cultured cortical neurons prepared from the ezrin knockdown (Vil2kd/kd) mice embryo that showed a very small amount of ezrin expression compared with the wild-type (Vil2+/+) neurons. Ezrin was mainly expressed in cell body in the cultured cortical neurons. We demonstrated that the cultured cortical neurons prepared from the Vil2kd/kd mice embryo exhibited impairment of neuritogenesis. Moreover, we observed increased RhoA activity and phosphorylation of myosin light chain 2 (MLC2), as a downstream effector of RhoA in the Vil2kd/kd neurons. In addition, inhibition of Rho kinase and myosin II rescued the impairment of neuritogenesis in the Vil2kd/kd neurons. These data altogether suggest a novel role of ezrin in the neuritogenesis of the cultured cortical neurons through down-regulation of RhoA activity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>Yosuke</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inden</LastName>
                    <ForeName>Masatoshi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamura</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Laboratory of Biological Science, Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hatano</LastName>
                    <ForeName>Ryo</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsukita</LastName>
                    <ForeName>Sachiko</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratory of Biological Science, Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asano</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105435</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-26445</ArticleId>
            <ArticleId IdType="pubmed">25144196</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25144131</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1533-4287</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of strength and conditioning research / National Strength &amp; Conditioning Association</Title>
                <ISOAbbreviation>J Strength Cond Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of Intestinal Microbiota on Exercise Performance in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The antioxidant enzyme system helps protect against intense exercise-induced oxidative damage and is related to the physical status of athletes. Evidence suggests that intestinal microbiota may be an important environmental factor associated with host metabolism, physiology, and antioxidant endogenous defense. However, evidence of the effect of gut microbiota status on exercise performance and physical fatigue is limited. We investigated the association of intestinal bacteria and exercise performance in specific pathogen-free (SPF), germ-free (GF), and Bacteroides fragilis (BF) gnotobiotic mice. Endurance swimming time was longer for SPF and BF than GF mice, and the weight of liver, muscle, brown adipose, and epididymal fat pads was higher for SPF and BF than GF mice. The serum levels of glutathione peroxidase (GPx) and catalase were greater in SPF than GF mice. Serum superoxide dismutase activity was lower in BF than SPF and GF mice. In addition, hepatic GPx level was higher in SPF than GF and BF mice. Gut microbial status could be crucial for exercise performance and its potential action linked with the antioxidant enzyme system in athletes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Yi-Ju</ForeName>
                    <Initials>YJ</Initials>
                    <Affiliation>1Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan 33301, Taiwan 2National Laboratory Animal Center, National Applied Research Laboratories, Taipei 11529, Taiwan 3Graduate Institute of Athletics and Coaching Science, National Taiwan Sport University, Taoyuan 33301, Taiwan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chiu</LastName>
                    <ForeName>Chien-Chao</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yen-Peng</ForeName>
                    <Initials>YP</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Wen-Ching</ForeName>
                    <Initials>WC</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Yen-Te</ForeName>
                    <Initials>YT</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Chi-Chang</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author>
                    <LastName>Chuang</LastName>
                    <ForeName>Hsiao-Li</ForeName>
                    <Initials>HL</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Strength Cond Res</MedlineTA>
            <NlmUniqueID>9415084</NlmUniqueID>
            <ISSNLinking>1064-8011</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1519/JSC.0000000000000644</ArticleId>
            <ArticleId IdType="pubmed">25144131</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedBookArticle>
    <BookDocument>
        <PMID Version="1">25144101</PMID>
        <ArticleIdList>
            <ArticleId IdType="bookaccession">NBK235149</ArticleId>
        </ArticleIdList>
        <Book>
            <Publisher>
                <PublisherName>National Academies Press (US)</PublisherName>
                <PublisherLocation>Washington (DC)</PublisherLocation>
            </Publisher>
            <BookTitle book="nap1429">Infectious Diseases of Mice and Rats</BookTitle>
            <PubDate>
                <Year>1991</Year>
            </PubDate>
            <AuthorList Type="authors">
                <Author>
                    <CollectiveName>National Research Council (US) Committee on Infectious Diseases of Mice and Rats</CollectiveName>
                </Author>
            </AuthorList>
            <CollectionTitle book="napcollect">The National Academies Collection: Reports funded by National Institutes of Health</CollectionTitle>
            <Isbn>0309063329</Isbn>
        </Book>
        <Language>eng</Language>
        <Abstract>
            <AbstractText>This new edition--a must for all researchers who use these lab animals-- provides practical suggestions for breeding, keeping, and identifying pathogen-free laboratory rodents. It contains three informative sections. The first, Principles of Rodent Disease Prevention, summarizes methods for eliminating infectious agents. It offers information on pathogen terminology; pathogen status of rodents; and breeding, transporting, isolating, testing, and diagnosing rodents. The second section, Individual Disease Agents and Their Effects on Research, describes the diagnosis and control of each infectious agent, and the last section, Diagnostic Indexes: Clinical Signs, Pathology, and Research Complications, contains informative tables covering all the diseases listed in the volume, arranged to help in the diagnosis of infected animals.</AbstractText>
            <CopyrightInformation>Copyright ?? 1991 by the National Academy of Sciences.</CopyrightInformation>
        </Abstract>
        <Sections>
            <Section>
                <SectionTitle book="nap1429" part="ddd00003">COMMITTEE ON INFECTIOUS DISEASES OF MICE AND RATS</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd00005">INSTITUTE OF LABORATORY ANIMAL RESOURCES COUNCIL</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd00007">COMMISSION ON LIFE SCIENCES</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd00009">PREFACE</SectionTitle>
            </Section>
            <Section>
                <LocationLabel Type="part">PART I</LocationLabel>
                <SectionTitle book="nap1429" part="ddd00011">PRINCIPLES OF RODENT DISEASE PREVENTION</SectionTitle>
                <Section>
                    <LocationLabel Type="chapter">1</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00012">Objectives, Terminology, and Overview of Pathogen Status</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">2</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00017">Breeding, Transportation, and Use of Pathogen-free Rodents</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">3</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00018">Barrier Programs</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">4</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00024">Health Surveillance Programs</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART II</LocationLabel>
                <SectionTitle book="nap1429" part="ddd00032">INDIVIDUAL DISEASE AGENTS AND THEIR EFFECTS ON RESEARCH</SectionTitle>
                <Section>
                    <LocationLabel Type="chapter">5</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00033">Introduction</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">6</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00034">Respiratory System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">7</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00192">Digestive System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">8</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00418">Skin and Joints</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">9</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00543">Hemopoietic System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">10</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00600">Central Nervous System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">11</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00623">Genitourinary System</SectionTitle>
                </Section>
                <Section>
                    <LocationLabel Type="chapter">12</LocationLabel>
                    <SectionTitle book="nap1429" part="ddd00647">Multiple Systems</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART III</LocationLabel>
                <SectionTitle book="nap1429" part="ddd00704">INDEXES TO DIAGNOSIS AND RESEARCH COMPLICATIONS OF INFECTIOUS AGENTS</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1429" part="ddd007090">REFERENCES</SectionTitle>
            </Section>
        </Sections>
    </BookDocument>
    <PubmedBookData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25144101</ArticleId>
        </ArticleIdList>
    </PubmedBookData>
</PubmedBookArticle>


<PubmedBookArticle>
    <BookDocument>
        <PMID Version="1">25144008</PMID>
        <ArticleIdList>
            <ArticleId IdType="bookaccession">NBK235403</ArticleId>
        </ArticleIdList>
        <Book>
            <Publisher>
                <PublisherName>National Academies Press (US)</PublisherName>
                <PublisherLocation>Washington (DC)</PublisherLocation>
            </Publisher>
            <BookTitle book="nap1540">Companion Guide to Infectious Diseases of Mice and Rats</BookTitle>
            <PubDate>
                <Year>1991</Year>
            </PubDate>
            <AuthorList Type="authors">
                <Author>
                    <CollectiveName>National Research Council (US) Committee on Infectious Diseases of Mice and Rats</CollectiveName>
                </Author>
            </AuthorList>
            <CollectionTitle book="napcollect">The National Academies Collection: Reports funded by National Institutes of Health</CollectionTitle>
            <Isbn>0309042836</Isbn>
        </Book>
        <Language>eng</Language>
        <Abstract>
            <AbstractText>This companion to Infectious Diseases of Mice and Rats makes practical information on rodent diseases readily accessible to researchers. This volume parallels the three parts of the main volume. Part I, Principles of Rodent Disease Prevention, briefly examines the requirements for maintaining pathogen-free rodents, factors in designing health surveillance programs, and other laboratory management issues. Part II, Disease Agents, is an easy-to-use reference section, listing diagnosis and control methods, the potential for interference with research, and other factors for disease agents ranging from adenoviruses to tapeworms. It covers bacteria, viruses, fungi and common ectoparasites, and endoparasites. Part III, Diagnostic Indexes, presents alphabetical listings of clinical signs, pathology, and research complications and lists infectious agents that might be responsible for each.</AbstractText>
            <CopyrightInformation>Copyright ?? 1991 by the National Academy of Sciences CIP.</CopyrightInformation>
        </Abstract>
        <Sections>
            <Section>
                <SectionTitle book="nap1540" part="ddd00003">COMMITTEE ON INFECTIOUS DISEASES OF MICE AND RATS</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1540" part="ddd00005">INSTITUTE OF LABORATORY ANIMAL RESOURCES COUNCIL</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1540" part="ddd00007">COMMISSION ON LIFE SCIENCES</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="nap1540" part="ddd00009">Preface</SectionTitle>
            </Section>
            <Section>
                <LocationLabel Type="part">PART I</LocationLabel>
                <SectionTitle book="nap1540" part="ddd00011">Principles of Rodent Disease Prevention</SectionTitle>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00012">SCIENTIFIC OBJECTIVES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00013">INFECTION VERSUS DISEASE</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00014">TERMINOLOGY OF MICROBIAL AND PATHOGEN STATUS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00015">COMMITMENT TO MAINTAINING PATHOGEN-FREE STATUS OF RODENTS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00016">HEALTH SURVEILLANCE PROGRAMS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00022">RODENT DIAGNOSTIC LABORATORIES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00023">REFERENCES</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART II</LocationLabel>
                <SectionTitle book="nap1540" part="ddd00024">Disease Agents</SectionTitle>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00025">BACTERIA, FUNGI, AND VIRUSES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00094">DERMATOPHYTES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00097">COMMON ECTOPARASITES</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00104">ENDOPARASITES</SectionTitle>
                </Section>
            </Section>
            <Section>
                <LocationLabel Type="part">PART III</LocationLabel>
                <SectionTitle book="nap1540" part="ddd00121">Diagnosis and Research Complications of Infectious Agents</SectionTitle>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00122">INTRODUCTION</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00123">CLINICAL SIGNS</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00124">PATHOLOGY</SectionTitle>
                </Section>
                <Section>
                    <SectionTitle book="nap1540" part="ddd00125">RESEARCH COMPLICATIONS</SectionTitle>
                </Section>
            </Section>
        </Sections>
    </BookDocument>
    <PubmedBookData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25144008</ArticleId>
        </ArticleIdList>
    </PubmedBookData>
</PubmedBookArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143992</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-744X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>TheScientificWorldJournal</Title>
                <ISOAbbreviation>ScientificWorldJournal</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phytoestrogen ??-Zearalanol Improves Memory Impairment and Hippocampal Neurogenesis in Ovariectomized Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>862019</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/862019</ELocationID>
            <Abstract>
                <AbstractText>Estrogen is known to provide robust protection of memory in postmenopausal women, but the fact that estrogen may increase the incidence of uterine and breast tumors has undoubtedly limited the clinical use of estrogen. In the present study, the effect of ??-zearalanol (??-ZAL), a plant-derived phytoestrogen with low side-effect on uterine and breast, on memory has been evaluated in ovariectomized (OVX) mice when using 17??-estradiol (17??-E2) as an estrogen positive control. Our findings demonstrated that OVX resulted in impaired spatial learning and memory and reduced numbers of newborn neurons in the dentate gyrus of the hippocampus, while 17??-E2 or ??-ZAL treatment significantly improved memory performance and restored hippocampal neurogenesis. We also found the reduction of brain derived neurotrophic factor (BDNF) and TrkB expression in OVX mice, which were ameliorated by 17??-E2 or ??-ZAL supplementation. These results indicated that ??-ZAL may improve memory impairments induced by OVX and modulate the expression of BDNF-TrkB benefit to neurogenesis which may be involved in the memory protection from ??-ZAL, in a manner similar to that of 17??-E2. The present findings suggested that ??-ZAL may be a plausible substitute of 17??-E2 in improving memory in postmenopausal women.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dong</LastName>
                    <ForeName>Yilong</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>School of Medicine, Yunnan University, Kunming, Yunnan 650091, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Aimei</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Hongju</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Huicheng</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>School of Medicine, Yunnan University, Kunming, Yunnan 650091, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yanmei</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>ScientificWorldJournal</MedlineTA>
            <NlmUniqueID>101131163</NlmUniqueID>
            <ISSNLinking>1537-744X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/862019</ArticleId>
            <ArticleId IdType="pubmed">25143992</ArticleId>
            <ArticleId IdType="pmc">PMC4131096</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143941</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gene delivery potential of biofunctional carbonate apatite nanoparticles in lungs.</ArticleTitle>
            <Pagination>
                <MedlinePgn>646787</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/646787</ELocationID>
            <Abstract>
                <AbstractText>Existing nonviral gene delivery systems to lungs are inefficient and associated with dose limiting toxicity in mammalian cells. Therefore, carbonate apatite (CO3Ap) nanoparticles were examined as an alternative strategy for effective gene delivery to the lungs. This study aimed to (1) assess the gene delivery efficiency of CO3Ap in vitro and in mouse lungs, (2) evaluate the cytotoxicity effect of CO3Ap/pDNA in vitro, and (3) characterize the CO3Ap/pDNA complex formulations. A significantly high level of reporter gene expression was detected from the lung cell line transfected with CO3Ap/pDNA complex prepared in both serum and serum-free medium. Cytotoxicity analysis revealed that the percentage of the viable cells treated with CO3Ap to be almost similar to the untreated cells. Characterization analyses showed that the CO3Ap/pDNA complexes are in a nanometer range with aggregated spherical structures and tended to be more negatively charged. In the lung of mice, highest level of transgene expression was observed when CO3Ap (8?????L) was complexed with 40?????g of pDNA at day 1 after administration. Although massive reduction of gene expression was seen beyond day 1 post administration, the level of expression remained significant throughout the study period.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alhaji</LastName>
                    <ForeName>Suleiman Yusuf</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Medical Genetics Laboratory, Clinical Genetics Unit, Faculty of Medicine and Health Sciences, UPM, 43400 Serdang, Selangor, Malaysia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chowdhury</LastName>
                    <ForeName>Ezharul Houque</ForeName>
                    <Initials>EH</Initials>
                    <Affiliation>Jeffry Cheah School of Medicine and Health Sciences, Monash University Malaysia, 46150 Bandar Sunway, Selangor, Malaysia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosli</LastName>
                    <ForeName>Rozita</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Medical Genetics Laboratory, Clinical Genetics Unit, Faculty of Medicine and Health Sciences, UPM, 43400 Serdang, Selangor, Malaysia ; UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, UPM, 43400 Serdang, Selangor, Malaysia ; Genetics &amp; Regenerative Medicine Research Centre, Faculty of Medicine &amp; Health Sciences, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassan</LastName>
                    <ForeName>Fatma</ForeName>
                    <Initials>F</Initials>
                    <Identifier Source="ORCID">0000-0003-4419-0064</Identifier>
                    <Affiliation>Molecular Pathology Research Group, Faculty of Pharmacy and Biotechnology, German University, New Cairo 11835, Egypt.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abdullah</LastName>
                    <ForeName>Syahril</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0003-2718-6266</Identifier>
                    <Affiliation>Medical Genetics Laboratory, Clinical Genetics Unit, Faculty of Medicine and Health Sciences, UPM, 43400 Serdang, Selangor, Malaysia ; UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, UPM, 43400 Serdang, Selangor, Malaysia ; Genetics &amp; Regenerative Medicine Research Centre, Faculty of Medicine &amp; Health Sciences, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/646787</ArticleId>
            <ArticleId IdType="pubmed">25143941</ArticleId>
            <ArticleId IdType="pmc">PMC4131073</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143871</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2167-0846</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>Suppl 3</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pain &amp; relief</Title>
                <ISOAbbreviation>J Pain Relief</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phenotypic Identification of Spinal Cord-Infiltrating CD4(+) T Lymphocytes in a Murine Model of Neuropathic Pain.</ArticleTitle>
            <Pagination>
                <MedlinePgn>003</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropathic pain is one of the most devastating kinds of chronic pain. Neuroinflammation has been shown to contribute to the development of neuropathic pain. We have previously demonstrated that lumbar spinal cord-infiltrating CD4(+) T lymphocytes contribute to the maintenance of mechanical hypersensitivity in spinal nerve L5 transection (L5Tx), a murine model of neuropathic pain. Here, we further examined the phenotype of the CD4(+) T lymphocytes involved in the maintenance of neuropathic pain-like behavior via intracellular flow cytometric analysis and explored potential interactions between infiltrating CD4(+) T lymphocytes and spinal cord glial cells.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We consistently observed significantly higher numbers of T-Bet(+), IFN-??(+), TNF-??(+), and GM-CSF(+), but not GATA3(+) or IL-4(+), lumbar spinal cord-infiltrating CD4(+) T lymphocytes in the L5Tx group compared to the sham group at day 7 post-L5Tx. This suggests that the infiltrating CD4(+) T lymphocytes expressed a pro-inflammatory type 1 phenotype (Th1). Despite the observation of CD4(+) CD40 ligand (CD154)(+) T lymphocytes in the lumbar spinal cord post-L5Tx, CD154 knockout (KO) mice did not display significant changes in L5Tx-induced mechanical hypersensitivity, indicating that T lymphocyte-microglial interaction through the CD154-CD40 pathway is not necessary for L5Tx-induced hypersensitivity. In addition, spinal cord astrocytic activation, represented by glial fibillary acidic protein (GFAP) expression, was significantly lower in CD4 KO mice compared to wild type (WT) mice at day 14 post-L5Tx, suggesting the involvement of astrocytes in the pronociceptive effects mediated by infiltrating CD4(+) T lymphocytes.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In all, these data indicate that the maintenance of L5Tx-induced neuropathic pain is mostly mediated by Th1 cells in a CD154-independent manner via a mechanism that could involve multiple Th1 cytokines and astrocytic activation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Draleau</LastName>
                    <ForeName>Ks</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Maddula</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Slaiby</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nutile-McMenemy</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>De Leo</LastName>
                    <ForeName>Ja</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA ; Vice President of Academic Affairs, Professor of Biology, Emmanuel College, 400 The Fenway, Boston, MA 02215, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cao</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME, 04005, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <GrantList>
                <Grant>
                    <GrantID>K01 DA023503</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Pain Relief</MedlineTA>
            <NlmUniqueID>101610026</NlmUniqueID>
            <ISSNLinking>2167-0846</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Astrocytes</Keyword>
            <Keyword MajorTopicYN="N">CD154 knockout mice</Keyword>
            <Keyword MajorTopicYN="N">CD4+ T lymphocytes</Keyword>
            <Keyword MajorTopicYN="N">Type 1 helper T cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2167-0846.S3-003</ArticleId>
            <ArticleId IdType="pubmed">25143871</ArticleId>
            <ArticleId IdType="pmc">PMC4136538</ArticleId>
            <ArticleId IdType="mid">NIHMS611217</ArticleId>
        </ArticleIdList>
        <?nihms?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143862</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2160-8407</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of nuclear medicine and molecular imaging</Title>
                <ISOAbbreviation>Am J Nucl Med Mol Imaging</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>435-47</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Personalized medicine is at the forefront of cancer diagnosis and therapy. Molecularly targeted therapies such as trastuzumab and tamoxifen have enhanced prognosis of patients with cancers expressing ERBB2 and the estrogen receptor, respectively. One obstacle to targeted therapy is the development of resistance. A targeted peptide that could distinguish resistance-susceptible cancer would aid in treatment. BT-474 human breast cancer cells can be resistant to both tamoxifen and trastuzumab, and may serve as a model for malignancies in which targeted therapy may not work. Bacteriophage (phage) display is a combinatorial technology that has been used to isolate peptides that target a specific cancer subtype. It was hypothesized that in vivo phage display could be used to select a peptide for SPECT imaging of BT-474 human breast cancer xenografts. A phage library displaying random 15 amino acid peptides was subjected to four rounds of selection, after which 14 clones were analyzed for BT-474 binding and specificity. One phage clone, 51, demonstrated superior binding and specificity, and the displayed peptide was synthesized for in vitro characterization. Peptide 51 bound specifically to BT-474 cells with an EC50 = 2.33 ??M and was synthesized as a DOTA-conjugated peptide and radiolabeled with (111)In for in vitro and in vivo analysis. The radiolabeled peptide exhibited an IC50 = 16.1 nM to BT-474 cells and its biodistribution and SPECT imaging in BT-474 xenografted mice was analyzed. Although tumor uptake was moderate at 0.11% ID/g, SPECT imaging revealed a distinct tumor vasculature binding pattern. It was discovered that peptide 51 had an identical 5 amino acid N-terminal sequence to a peptide, V1, which bound to Nrp1, a tumor vasculature protein. Peptide 51 and V1 were examined for binding to target cells, and 51 bound both target and endothelial cells, while V1 only bound endothelial cells. Truncated versions of 51 did not bind BT-474 cells, demonstrating that the targeting ability of 51 was independent of the homologous V1 sequence. These results demonstrate that in vivo phage display can effectively identify a peptide that specifically targets a breast cancer cell line that is susceptible to targeted therapy resistance.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Larimer</LastName>
                    <ForeName>Benjamin M</ForeName>
                    <Initials>BM</Initials>
                    <Affiliation>Research Services, Harry S. Truman Veterans Affairs Hospital Columbia, MO ; Department of Biochemistry, University of Missouri Columbia, MO.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deutscher</LastName>
                    <ForeName>Susan L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Research Services, Harry S. Truman Veterans Affairs Hospital Columbia, MO ; Department of Biochemistry, University of Missouri Columbia, MO.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Nucl Med Mol Imaging</MedlineTA>
            <NlmUniqueID>101564121</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Peptide</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">molecular imaging</Keyword>
            <Keyword MajorTopicYN="N">phage display</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25143862</ArticleId>
            <ArticleId IdType="pmc">PMC4138138</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143818</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2001-0001</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Pathobiology of aging &amp; age related diseases</Title>
                <ISOAbbreviation>Pathobiol Aging Age Relat Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Investigation and identification of etiologies involved in the development of acquired hydronephrosis in aged laboratory mice with the use of high-frequency ultrasound imaging.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3402/pba.v4.24932</ELocationID>
            <Abstract>
                <AbstractText>Laboratory mice develop naturally occurring lesions that affect biomedical research. Hydronephrosis is a recognized pathologic abnormality of the mouse kidney. Acquired hydronephrosis can affect any mouse, as it is caused by any naturally occurring disease that impairs free urine flow. Many etiologies leading to this condition are of particular significance to aging mice. Non-invasive ultrasound imaging detects renal pelvic dilation, renal enlargement, and parenchymal loss for pre-mortem identification of this condition. High-frequency ultrasound transducers produce high-resolution images of small structures, ideal for detecting organ pathology in mice. Using a 40 MHz linear array transducer, we obtained high-resolution images of a diversity of pathologic lesions occurring within the abdomen of seven geriatric mice with acquired hydronephrosis that enabled a determination of the underlying etiology. Etiologies diagnosed from the imaging results include pyelonephritis, neoplasia, urolithiasis, mouse urologic syndrome, and spontaneous hydronephrosis, and were confirmed at necropsy. A retrospective review of abdominal scans from an additional 149 aging mice shows that the most common etiologies associated with acquired hydronephrosis are mouse urologic syndrome and abdominal neoplasia. This report highlights the utility of high-frequency ultrasound for surveying research mice for age-related pathology, and is the first comprehensive report of multiple cases of acquired hydronephrosis in mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Springer</LastName>
                    <ForeName>Danielle A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Murine Phenotyping Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allen</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Murine Phenotyping Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffman</LastName>
                    <ForeName>Victoria</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brinster</LastName>
                    <ForeName>Lauren</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Starost</LastName>
                    <ForeName>Matthew F</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bryant</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eckhaus</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Office of Research Services, Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Sweden</Country>
            <MedlineTA>Pathobiol Aging Age Relat Dis</MedlineTA>
            <NlmUniqueID>101575310</NlmUniqueID>
            <ISSNLinking>2001-0001</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">abdominal imaging</Keyword>
            <Keyword MajorTopicYN="N">abdominal neoplasia</Keyword>
            <Keyword MajorTopicYN="N">hydronephrosis</Keyword>
            <Keyword MajorTopicYN="N">kidney</Keyword>
            <Keyword MajorTopicYN="N">mice</Keyword>
            <Keyword MajorTopicYN="N">mouse urologic syndrome</Keyword>
            <Keyword MajorTopicYN="N">pathology</Keyword>
            <Keyword MajorTopicYN="N">renal pelvic dilation</Keyword>
            <Keyword MajorTopicYN="N">ultrasound</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3402/pba.v4.24932</ArticleId>
            <ArticleId IdType="pii">24932</ArticleId>
            <ArticleId IdType="pubmed">25143818</ArticleId>
            <ArticleId IdType="pmc">PMC4119937</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143817</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dependence Potential of the Synthetic Cannabinoids JWH-073, JWH-081, and JWH-210: In Vivo and In Vitro Approaches.</ArticleTitle>
            <Pagination>
                <MedlinePgn>363-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.039</ELocationID>
            <Abstract>
                <AbstractText>Synthetic cannabinoids (CBs) such as the JWH series have caused social problems concerning their abuse liability. Because the JWH series produces euphoric and hallucinogenic effects, they have been distributed illegally under street names such as &quot;Spice&quot; and &quot;Smoke&quot;. Many countries including Korea have started to schedule some of the JWH series compounds as controlled substances, but there are a number of JWH series chemicals that remain uncontrolled by law. In this study, three synthetic CBs with different binding affinities to the CB1 receptor (JWH-073, 081, and 210) and ??(9)-tetrahydrocannabinol (??(9)-THC) were evaluated for their potential for psychological dependence. The conditioned place preference test (unbiased method) and self-administration test (fixed ratio of 1) using rodents were conducted. Ki values of the three synthetic cannabinoids were calculated as supplementary data using a receptor binding assay and overexpressed CB1 protein membranes to compare dependence potential with CB1 receptor binding affinity. All mice administered JWH-073, 081, or 210 showed significantly increased time spent at unpreferred space in a dose-dependence manner in the conditioned place preference test. In contrast, all tested substances except ??(9)-THC showed aversion phenomenon at high doses in the conditioned place preference test. The order of affinity to the CB1 receptor in the receptor binding assay was JWH-210 &gt; JWH-081 &gt; JWH-073, which was in agreement with the results from the conditioned place preference test. However, no change in self-administration was observed. These findings suggest the possibility to predict dependence potential of synthetic CBs through a receptor binding assay at the screening level.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cha</LastName>
                    <ForeName>Hye Jin</ForeName>
                    <Initials>HJ</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700 ; Department of Infectious Diseases, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Kwang-Wook</ForeName>
                    <Initials>KW</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Min-Ji</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyeon</LastName>
                    <ForeName>Yang-Jin</ForeName>
                    <Initials>YJ</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Ji-Young</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon 440-746.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jang</LastName>
                    <ForeName>Choon-Gon</ForeName>
                    <Initials>CG</Initials>
                    <Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon 440-746.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Joon-Ik</ForeName>
                    <Initials>JI</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeon</LastName>
                    <ForeName>Seol-Hee</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Hyun-Uk</ForeName>
                    <Initials>HU</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Young-Hoon</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seong</LastName>
                    <ForeName>Won-Keun</ForeName>
                    <Initials>WK</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Hoil</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoo</LastName>
                    <ForeName>Han Sang</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Department of Infectious Diseases, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeong</LastName>
                    <ForeName>Ho-Sang</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju 363-700.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Binding affinity</Keyword>
            <Keyword MajorTopicYN="N">CB1 receptor</Keyword>
            <Keyword MajorTopicYN="N">Psychological dependence</Keyword>
            <Keyword MajorTopicYN="N">Synthetic cannabinoid</Keyword>
            <Keyword MajorTopicYN="N">??9-Tetrahydrocannabinol (??9-THC)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.039</ArticleId>
            <ArticleId IdType="pii">bt-22-363</ArticleId>
            <ArticleId IdType="pubmed">25143817</ArticleId>
            <ArticleId IdType="pmc">PMC4131522</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143814</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antitumor and Apoptosis Induction Effects of Paeonol on Mice Bearing EMT6 Breast Carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>341-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2013.106</ELocationID>
            <Abstract>
                <AbstractText>Paeonol is a major phenolic micromolecular component of Moutan cortex Radicis, a traditional Chinese Medicine. It has shown antitumor effects in previous studies; however, the underlying mechanisms remain unknown. This study investigated the mechanism by giving treatments of placebo, cyclophosphamide, paeonol of 150 and 300 mg/kg to 4 groups of mice bearing EMT6 breast cancer. Apoptosis in tumor cells were confirmed by morphology analysis, including hematoxylin, eosin staining and TUNEL staining. The results showed that the weight of EMT6 breast tumor was significantly reduced in the groups treated with both 150 and 300 mg/kg of paeonol. Immunohistochemical and Western blot results showed that the expression of Bcl-2 was down-regulated while the expression of Bax, caspase 8 and caspase 3 was up-regulated respectively. These results suggest that paeonol exhibits antitumor effects and the mechanism of the inhibition is via induction of apoptosis, regulation of Bcl-2 and Bax expression, and activation of caspase 8 and caspase 3.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ou</LastName>
                    <ForeName>Yetao</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Biological Engineering, College of Environment and Chemical Engineering, Yanshan University, Qinghuangdao 066004 ; College of Basic Medicine, Jiamusi University, Jiamusi 154007, P. R China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Qingwang</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Biological Engineering, College of Environment and Chemical Engineering, Yanshan University, Qinghuangdao 066004 ; College of Animal Science, Northwest A&amp;F University, Yangling 712100.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jianjie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>College of Basic Medicine, Jiamusi University, Jiamusi 154007, P. R China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Kun</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Biological Engineering, College of Environment and Chemical Engineering, Yanshan University, Qinghuangdao 066004.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Shaobo</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Life Science, Institute of Biomedical and Environmental Science and Technology, University of Bedfordshire, Luton, LU1 3JU, UK.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Paeonol</Keyword>
            <Keyword MajorTopicYN="N">Pathway</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2013.106</ArticleId>
            <ArticleId IdType="pii">bt-22-341</ArticleId>
            <ArticleId IdType="pubmed">25143814</ArticleId>
            <ArticleId IdType="pmc">PMC4131527</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143812</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adipose-derived stem cells improve efficacy of melanocyte transplantation in animal skin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>328-33</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.065</ELocationID>
            <Abstract>
                <AbstractText>Vitiligo is a pigmentary disorder induced by a loss of melanocytes. In addition to replacement of pure melanocytes, cocultures of melanocytes with keratinocytes have been used to improve the repigmentation outcome in vitiligo treatment. We previously identified by in vitro studies, that adipose-derived stem cells (ADSCs) could be a potential substitute for keratinocytes in cocultures with melanocytes. In this study, the efficacy of pigmentation including durability of grafted melanocytes and short-term safety was examined in the nude mouse and Sprague-Dawley rat after grafting of primary cultured human melanocytes, with or without different ratios of primary cultured human ADSCs. Simultaneous grafting of melanocytes and ADSCs, which were separately cultured and mixed on grafting at the ratios of 1:1, 1:2, or 1:3, showed better efficacy than that of pure melanocytes. Grafting of melanocytes cocultured with ADSCs resulted in a similar outcome as the grafting of cell mixtures. Skin pigmentation by melanocytes : ADSCs at the ratios of 1:1 and 1:2 was better than at 1:3. No significant difference was observed between the 1-week and 2-week durations in coculturing. Time-course microscopic examination showed that the grafted melanocytes remained a little longer than 6-week post-grafting. No inflammatory cell infiltration was observed in the grafted skin and no melanocytes were detectable in other organs. Collectively, grafting of melanocytes and ADSCs was equally safe and more effective than grafting of melanocytes alone. Despite the absence of significant differences in efficacy between the group of 1:1 and that of 1:2 ratio, 1:2 ratio for 1-week coculturing may be better for clinical use from the cost-benefit viewpoint.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Won-Suk</ForeName>
                    <Initials>WS</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Chang-Hyun</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ji-Young</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Do</LastName>
                    <ForeName>Byung-Rok</ForeName>
                    <Initials>BR</Initials>
                    <Affiliation>Biotechnology Research Institute, Hurim BioCell Inc., Seoul 157-793, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Eo Jin</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Pathology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Ai-Young</ForeName>
                    <Initials>AY</Initials>
                    <Affiliation>Departments of Dermatology, Dongguk University Ilsan Hospital, Goyang 410-773.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adipose-derived stem cells</Keyword>
            <Keyword MajorTopicYN="N">Animal</Keyword>
            <Keyword MajorTopicYN="N">Efficacy</Keyword>
            <Keyword MajorTopicYN="N">Grafting</Keyword>
            <Keyword MajorTopicYN="N">Melanocytes</Keyword>
            <Keyword MajorTopicYN="N">Short-term safety</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.065</ArticleId>
            <ArticleId IdType="pii">bt-22-328</ArticleId>
            <ArticleId IdType="pubmed">25143812</ArticleId>
            <ArticleId IdType="pmc">PMC4131530</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143811</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).</ArticleTitle>
            <Pagination>
                <MedlinePgn>321-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.053</ELocationID>
            <Abstract>
                <AbstractText>Collagen pentapeptide (Lys-Thr-Thr-Lys-Ser, KTTKS) and its palmitoylated derivative (pal-KTTKS) have received a great deal of attention as cosmeceutical ingredients for their anti-wrinkle effects. The objective of this study was to evaluate stability and permeability of KTTKS and pal-KTTKS in hairless mouse skin. In this study, a liquid chromatography-tandem mass spectrometric method was developed for the quantification of pal-KTTKS, and used for stability and permeability studies. Stability studies were performed using skin extracts and homogenates. Both KTTKS and pal-KTTKS were rapidly degraded, but pal-KTTKS was more stable than KTTKS. When protease inhibitors were added, the stability of both compounds (KTTKS and pal-KTTKS) improved significantly. In the skin permeation study, neither KTTKS nor pal-KTTKS was detected in the receptor solution, which indicates that neither compound could permeate through the full-thickness hairless mouse skin in the experimental conditions of this study. While KTTKS was not detected in any of the skin layers (the stratum corneum, epidermis, and dermis), pal-KTTKS was observed in all skin layers: 4.2 ?? 0.7 ??g/cm(2) in the stratum corneum, 2.8 ?? 0.5 ??g/cm(2) in the epidermis, and 0.3 ?? 0.1 ??g/cm(2) in the dermis. In conclusion, this study indicated that pal-KTTKS had greater stability and permeability than that of un-modified KTTKS, and may be a useful anti-wrinkle and anti-aging cosmeceutical agent.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Yun Lim</ForeName>
                    <Initials>YL</Initials>
                    <Affiliation>College of Pharmacy, Kyungsung University, Busan 608-736.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Eun Ji</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 702-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Eunje</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>College of Pharmacy, Kyungsung University, Busan 608-736.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Na</LastName>
                    <ForeName>Dong Hee</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 702-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Young-Hee</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>College of Pharmacy, Kyungsung University, Busan 608-736.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Collagen pentapeptide</Keyword>
            <Keyword MajorTopicYN="N">KTTKS</Keyword>
            <Keyword MajorTopicYN="N">Palmitoyl-KTTKS</Keyword>
            <Keyword MajorTopicYN="N">Permeability</Keyword>
            <Keyword MajorTopicYN="N">Stability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.053</ArticleId>
            <ArticleId IdType="pii">bt-22-321</ArticleId>
            <ArticleId IdType="pubmed">25143811</ArticleId>
            <ArticleId IdType="pmc">PMC4131521</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143810</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pachymic Acid Enhances Pentobarbital-Induced Sleeping Behaviors via GABAA-ergic Systems in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>314-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.045</ELocationID>
            <Abstract>
                <AbstractText>This study was investigated to know whether pachymic acid (PA), one of the predominant triterpenoids in Poria cocos (Hoelen) has the sedative-hypnotic effects, and underlying mechanisms are mediated via ??-aminobutyric acid (GABA)-ergic systems. Oral administration of PA markedly suppressed locomotion activity in mice. This compound also prolonged sleeping time, and reduced sleep latency showing synergic effects with muscimol (0.2 mg/kg) in shortening sleep onset and enhancing sleep time induced by pentobarbital, both at the hypnotic (40 mg/kg) and sub-hypnotic (28 mg/kg) doses. Additionally, PA elevated intracellular chloride levels in hypothalamic primary cultured neuronal cells of rats. Moreover, Western blotting quantitative results showed that PA increased the amount of protein level expression of GAD65/67 over a broader range of doses. PA increased ??- and ??-subunits protein levels, but decreased ??-subunit protein levels in GABAA receptors. The present experiment provides evidence for the hypnotic effects as PA enhanced pentobarbital-induced sleeping behaviors via GABAA-ergic mechanisms in rodents. Taken together, it is proposed that PA may be useful for the treatment of sleep disturbed subjects with insomnia.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>Vikash Kumar</ForeName>
                    <Initials>VK</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Jae Joon</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Jin-Yi</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>Institute of Veterinary Medicine, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Mi Kyeong</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hong</LastName>
                    <ForeName>Jin Tae</ForeName>
                    <Initials>JT</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oh</LastName>
                    <ForeName>Ki-Wan</ForeName>
                    <Initials>KW</Initials>
                    <Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GABAA receptors</Keyword>
            <Keyword MajorTopicYN="N">Glutamic acid decarboxylase (GAD)</Keyword>
            <Keyword MajorTopicYN="N">Insomnia</Keyword>
            <Keyword MajorTopicYN="N">Pachymic acid (PA)</Keyword>
            <Keyword MajorTopicYN="N">Pentobarbital (PENT)</Keyword>
            <Keyword MajorTopicYN="N">Poria cocos (Hoelen)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.045</ArticleId>
            <ArticleId IdType="pii">bt-22-314</ArticleId>
            <ArticleId IdType="pubmed">25143810</ArticleId>
            <ArticleId IdType="pmc">PMC4131518</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143803</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1976-9148</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomolecules &amp; therapeutics</Title>
                <ISOAbbreviation>Biomol Ther (Seoul)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetically engineered mouse models for drug development and preclinical trials.</ArticleTitle>
            <Pagination>
                <MedlinePgn>267-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4062/biomolther.2014.074</ELocationID>
            <Abstract>
                <AbstractText>Drug development and preclinical trials are challenging processes and more than 80% to 90% of drug candidates fail to gain approval from the United States Food and Drug Administration. Predictive and efficient tools are required to discover high quality targets and increase the probability of success in the process of new drug development. One such solution to the challenges faced in the development of new drugs and combination therapies is the use of low-cost and experimentally manageable in vivo animal models. Since the 1980's, scientists have been able to genetically modify the mouse genome by removing or replacing a specific gene, which has improved the identification and validation of target genes of interest. Now genetically engineered mouse models (GEMMs) are widely used and have proved to be a powerful tool in drug discovery processes. This review particularly covers recent fascinating technologies for drug discovery and preclinical trials, targeted transgenesis and RNAi mouse, including application and combination of inducible system. Improvements in technologies and the development of new GEMMs are expected to guide future applications of these models to drug discovery and preclinical trials.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Ho</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Division of Convergence Technology, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 410-769, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Biomol Ther (Seoul)</MedlineTA>
            <NlmUniqueID>101472832</NlmUniqueID>
            <ISSNLinking>1976-9148</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Drug discovery</Keyword>
            <Keyword MajorTopicYN="N">Genetically engineered mouse models</Keyword>
            <Keyword MajorTopicYN="N">Preclinical trials</Keyword>
            <Keyword MajorTopicYN="N">RNAi mouse</Keyword>
            <Keyword MajorTopicYN="N">Targeted transgenesis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2014.074</ArticleId>
            <ArticleId IdType="pii">bt-22-267</ArticleId>
            <ArticleId IdType="pubmed">25143803</ArticleId>
            <ArticleId IdType="pmc">PMC4131519</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143786</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1758-5996</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetology &amp; metabolic syndrome</Title>
                <ISOAbbreviation>Diabetol Metab Syndr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>83</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1758-5996-6-83</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In addition to their role in growth, cellular differentiation and homeostasis Retinoid X Receptors (RXR) regulate multiple physiological and metabolic pathways in various organs that have beneficial glucose and lipid (cholesterol) lowering, insulin sensitizing and anti-obesity effects. Rexinoids, compounds that specifically binds and activate RXR, are therefore considered as potential therapeutics for treating metabolic syndrome. Apparently many of the rexinoids developed in the past increased triglycerides, caused hepatomegaly and also suppressed the thyroid hormone axis. The aim of this study is to evaluate CNX-013-B2, a potent and highly selective rexinoid, for its potential to treat multiple risk factors of the metabolic syndrome.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">CNX-013-B2 was selected in a screening system designed to identify compounds that selectively activated only a chosen sub-set of heterodimer partners of RXR of importance to treat insulin resistance. Male C57BL/6j mice (n???=???10) on high fat diet (HFD) and 16 week old ob/ob mice (n???=???8) were treated orally with CNX-013-B2 (10 mg/kg twice daily) or vehicle for 10 weeks and 4 weeks respectively. Measurement of plasma glucose, triglyceride, cholesterol including LDL-C, glycerol, free fatty acids, feed intake, body weight, oral glucose tolerance and non-shivering thermogenesis were performed at selected time points. After study termination such measurements as organ weight, triglyceride content, mRNA levels, protein phosphorylation along with histological analysis were performed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">CNX-013-B2 selectively activates PPARs- ??, ??/?? and ?? and modulates activity of LXR, THR and FXR. In ob/ob mice a significant reduction of 25% in fed glucose (p???&lt;???0.001 ), a 14% (p???&lt;???0.05) reduction in serum total cholesterol and 18% decrease (p???&lt;???0.01) in LDL-C and in DIO mice a reduction of 12% (p???&lt;???0.01 ) in fasting glucose, 20% in fed triglyceride (p???&lt;???0.01) and total cholesterol (p???&lt;???0.001) levels, coupled with enhanced insulin sensitivity, cold induced thermogenesis and 7% reduction in body weight were observed.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CNX-013-B2 is an orally bio available selective rexinoid that can be used as a novel therapeutic agent for management of multiple risk factors of the metabolic syndrome without the risk of side effects reported to be associated with rexinoids.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sadasivuni</LastName>
                    <ForeName>Manoj Kumar</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>Bobbili Madhusudhan</ForeName>
                    <Initials>BM</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Jaideep</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anup</LastName>
                    <ForeName>Mammen O</ForeName>
                    <Initials>MO</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sunil</LastName>
                    <ForeName>Venkategowda</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lakshmi</LastName>
                    <ForeName>Mudigere N</ForeName>
                    <Initials>MN</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yogeshwari</LastName>
                    <ForeName>Sivakumaran</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chacko</LastName>
                    <ForeName>Suni K</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pooja</LastName>
                    <ForeName>Talanki Lokesh</ForeName>
                    <Initials>TL</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dandu</LastName>
                    <ForeName>Anilkumar</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harish</LastName>
                    <ForeName>Chandrashekaran</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gopala</LastName>
                    <ForeName>Aralakuppe S</ForeName>
                    <Initials>AS</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pratibha</LastName>
                    <ForeName>Shivakumar</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naveenkumar</LastName>
                    <ForeName>Baisani S</ForeName>
                    <Initials>BS</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pallavi</LastName>
                    <ForeName>Puttrevana M</ForeName>
                    <Initials>PM</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verma</LastName>
                    <ForeName>Mahesh Kumar</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moolemath</LastName>
                    <ForeName>Yoganand</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Somesh</LastName>
                    <ForeName>Baggavalli P</ForeName>
                    <Initials>BP</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Venkataranganna</LastName>
                    <ForeName>Marikunte V</ForeName>
                    <Initials>MV</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jagannath</LastName>
                    <ForeName>Madanahalli R</ForeName>
                    <Initials>MR</Initials>
                    <Affiliation>Connexios Life Sciences Pvt Ltd, Bangalore, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Diabetol Metab Syndr</MedlineTA>
            <NlmUniqueID>101488958</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CHF</Keyword>
            <Keyword MajorTopicYN="N">Diabetes</Keyword>
            <Keyword MajorTopicYN="N">Dyslipidemia</Keyword>
            <Keyword MajorTopicYN="N">Exercise mimetic</Keyword>
            <Keyword MajorTopicYN="N">Insulin sensitizer</Keyword>
            <Keyword MajorTopicYN="N">PPAR pan-activator</Keyword>
            <Keyword MajorTopicYN="N">Steatosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-5996-6-83</ArticleId>
            <ArticleId IdType="pii">348</ArticleId>
            <ArticleId IdType="pubmed">25143786</ArticleId>
            <ArticleId IdType="pmc">PMC4138375</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25143767</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1735-4668</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Season>Summer</Season>
                    </PubDate>
                </JournalIssue>
                <Title>Iranian journal of child neurology</Title>
                <ISOAbbreviation>Iran J Child Neurol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Familial hemiplegic migraine and spreading depression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6-11</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Familial hemiplegic migraine (FHM) is an autosomal dominantly inherited subtype of migraine with aura, characterized by transient neurological signs and symptoms. Typical hemiplegic migraine attacks start in the first or second decade of life. Some patients with FHM suffer from daily recurrent attacks since childhood. Results from extensive studies of cellular and animal models have indicated that gene mutations in FHM increase neuronal excitability and reduce the threshold for spreading depression (SD). SD is a transient wave of profound neuronal and glial depolarization that slowly propagates throughout the brain tissue and is characterized by a high amplitude negative DC shift. After induction of SD, S218L mutant mice exhibited neurological signs highly reminiscent of clinical attacks in FHM type 1 patients carrying this mutation. FHM1 with ataxia is attributable to specific mutations that differ from mutations that cause pure FHM1 and have peculiar consequences on cerebellar Cav2.1 currents that lead to profound Purkinje cell dysfunction and neuronal loss with atrophy. SD in juvenile rats produced neuronal injury and death. Hormonal factors involved in FHM affect SD initiation and propagation. The data identify SD as a possible target of treatment of FHM. In addition, FHM is a useful model to explore the mechanisms of more common types of migraine.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kazemi</LastName>
                    <ForeName>Hadi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Pediatric, Shahed University, Tehran, Iran ; Shefa Neuroscience Research Center, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Speckmann</LastName>
                    <ForeName>Erwin-Josef</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Epilepsy Research Center, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Institut f??r Physiologie I, Westf??lische Wilhelms-Universit??t M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gorji</LastName>
                    <ForeName>Ali</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Shefa Neuroscience Research Center, Tehran, Iran ; Epilepsy Research Center, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Institut f??r Physiologie I, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Klinik und Poliklinik f??r Neurochirurgie, Westf??lische Wilhelms-Universit??t M??nster, Germany ; Department ofNeurology, Westf??lische Wilhelms-Universit??t M??nster, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Iran J Child Neurol</MedlineTA>
            <NlmUniqueID>101463836</NlmUniqueID>
            <ISSNLinking>1735-4668</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cerebrovascular diseases</Keyword>
            <Keyword MajorTopicYN="N">Children</Keyword>
            <Keyword MajorTopicYN="N">Headache</Keyword>
            <Keyword MajorTopicYN="N">Spreading depolarization</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25143767</ArticleId>
            <ArticleId IdType="pmc">PMC4135274</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143734</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1178-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of nanomedicine</Title>
                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3865-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S62630</ELocationID>
            <Abstract>
                <AbstractText>Primaquine (PQ) is one of the most widely used antimalarial drugs and is the only available drug that combats the relapsing form of malaria. PQ use in higher doses is limited by severe tissue toxicity including hematological- and gastrointestinal-related side effects. Nanoformulation of drugs in an appropriate drug carrier system has been extensively studied and shown to have the potential to improve bioavailability, thereby enhancing activity, reducing dose frequency, and subsequently reducing toxicity. The aim of this work was to design, synthesize, and characterize PQ-loaded solid lipid nanoparticles (SLNs) (PQ-SLNs) as a potential drug-delivery system. SLNs were prepared by a modified solvent emulsification evaporation method based on a water-in-oil-in-water (w/o/w) double emulsion. The mean particle size, zeta potential, drug loading, and encapsulation efficiency of the PQ-SLNs were 236 nm, +23 mV, 14%, and 75%, respectively. The zeta potential of the SLNs changed dramatically, from -6.54 mV to +23.0 mV, by binding positively charged chitosan as surface modifier. A spherical morphology of PQ-SLNs was seen by scanning electron microscope. In vitro, release profile depicted a steady drug release over 72 hours. Differential scanning calorimeter thermograms demonstrated presence of drug in drug-loaded nanoparticles along with disappearance of decomposition exotherms, suggesting increased physical stability of drug in prepared formulations. Negligible changes in characteristic peaks of drug in Fourier transform infrared spectra indicated absence of any interaction among the various components entrapped in the nanoparticle formulation. The nanoformulated PQ was 20% more effective as compared with conventional oral dose when tested in Plasmodium berghei-infected Swiss albino mice. This study demonstrated an efficient method of forming a nanomedicine delivery system for antimalarial drugs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Omwoyo</LastName>
                    <ForeName>Wesley Nyaigoti</ForeName>
                    <Initials>WN</Initials>
                    <Affiliation>Department of Chemistry, Maasai Mara University, Narok, Kenya ; Department of Chemistry, Jaramogi Oginga Odinga University of Science and Technology, Bondo, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogutu</LastName>
                    <ForeName>Bernhards</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya ; Kenya Medical Research Institute, Nairobi, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oloo</LastName>
                    <ForeName>Florence</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya ; Department of Chemical Sciences and Technology, Technical University of Kenya, Nairobi, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swai</LastName>
                    <ForeName>Hulda</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Polymers and Composites, Council for Scientific and Industrial Research, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalombo</LastName>
                    <ForeName>Lonji</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Polymers and Composites, Council for Scientific and Industrial Research, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Melariri</LastName>
                    <ForeName>Paula</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Polymers and Composites, Council for Scientific and Industrial Research, Pretoria, South Africa.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahanga</LastName>
                    <ForeName>Geoffrey Maroa</ForeName>
                    <Initials>GM</Initials>
                    <Affiliation>Department of Chemistry, Jaramogi Oginga Odinga University of Science and Technology, Bondo, Kenya.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gathirwa</LastName>
                    <ForeName>Jeremiah Waweru</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya ; Kenya Medical Research Institute, Nairobi, Kenya.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Int J Nanomedicine</MedlineTA>
            <NlmUniqueID>101263847</NlmUniqueID>
            <ISSNLinking>1176-9114</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antimalarial</Keyword>
            <Keyword MajorTopicYN="N">double emulsion</Keyword>
            <Keyword MajorTopicYN="N">nanomedicine drug-delivery system</Keyword>
            <Keyword MajorTopicYN="N">nanotechnology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S62630</ArticleId>
            <ArticleId IdType="pii">ijn-9-3865</ArticleId>
            <ArticleId IdType="pubmed">25143734</ArticleId>
            <ArticleId IdType="pmc">PMC4137995</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143732</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1178-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of nanomedicine</Title>
                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3841-53</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S64630</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Currently approved therapies for multiple sclerosis (MS) at best only slow down its progression. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In the present study, for the first time we evaluated the therapeutic potential of MSc1 nanocomplex, which was designed based on novel nanochelating technology.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">MSc1 cell-protection capacity, with and without iron bond, was evaluated against hydrogen peroxide (H2O2)-induced oxidative stress in cultured rat pheochromocytoma-12 cells. The ability of MSc1 to maintain iron bond at pH ranges of 1-7 was evaluated. Nanocomplex toxicity was examined by estimating the intraperitoneal median lethal dose (LD50). Experimental autoimmune encephalomyelitic mice were injected with MSc1 14 days after disease induction, when the clinical symptoms appeared. The clinical score, body weight, and disease-induced mortality were monitored until day 54. In the end, after collecting blood samples for assessing hemoglobin and red blood cell count, the brains and livers of the mice were isolated for hematoxylin and eosin staining and analysis of iron content, respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed that MSc1 prevented H2O2-induced cell death even after binding with iron, and it preserved its bond with iron constant at pH ranges 1-7. The nanocomplex intraperitoneal LD50 was 1,776.59 mg/kg. MSc1 prompted therapeutic behavior and improved the disabling features of experimental autoimmune encephalomyelitis, which was confirmed by decreased clinical scores versus increased body mass and 100% survival probability. It did not cause any adverse effects on hemoglobin or red blood cell count. Histopathological studies showed no neural loss or lymphocyte infiltration in MSc1-treated mice, while the hepatic iron content was also normal.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrate that MSc1 could be a promising beneficial novel agent and has the capacity to be evaluated in further studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fakharzadeh</LastName>
                    <ForeName>Saideh</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sahraian</LastName>
                    <ForeName>Mohammad Ali</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hafizi</LastName>
                    <ForeName>Maryam</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalanaky</LastName>
                    <ForeName>Somayeh</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masoumi</LastName>
                    <ForeName>Zahra</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahdavi</LastName>
                    <ForeName>Mehdi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamalian</LastName>
                    <ForeName>Nasser</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Pathology, Medical School of Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Minagar</LastName>
                    <ForeName>Alireza</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neurology, LSU Health Sciences Centre, Shreveport, LA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nazaran</LastName>
                    <ForeName>Mohammad Hassan</ForeName>
                    <Initials>MH</Initials>
                    <Affiliation>Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Int J Nanomedicine</MedlineTA>
            <NlmUniqueID>101263847</NlmUniqueID>
            <ISSNLinking>1176-9114</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EAE</Keyword>
            <Keyword MajorTopicYN="N">MSc1</Keyword>
            <Keyword MajorTopicYN="N">multiple sclerosis</Keyword>
            <Keyword MajorTopicYN="N">nanochelating technology</Keyword>
            <Keyword MajorTopicYN="N">nanocomplex</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S64630</ArticleId>
            <ArticleId IdType="pii">ijn-9-3841</ArticleId>
            <ArticleId IdType="pubmed">25143732</ArticleId>
            <ArticleId IdType="pmc">PMC4137990</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25143731</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1178-2013</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of nanomedicine</Title>
                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3825-39</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S65990</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We have previously demonstrated the epidermal growth factor receptor (EGFR)-targeted hybrid plasmonic magnetic nanoparticles (225-NP) produce a therapeutic effect in human lung cancer cell lines in vitro. In the present study, we investigated the molecular mechanism of 225-NP-mediated antitumor activity both in vitro and in vivo using the EGFR-mutant HCC827 cell line.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The growth inhibitory effect of 225-NP on lung tumor cells was determined by cell viability and cell-cycle analysis. Protein expression related to autophagy, apoptosis, and DNA-damage were determined by Western blotting and immunofluorescence. An in vivo efficacy study was conducted using a human lung tumor xenograft mouse model.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 225-NP treatment markedly reduced tumor cell viability at 72 hours compared with the cell viability in control treatment groups. Cell-cycle analysis showed the percentage of cells in the G2/M phase was reduced when treated with 225-NP, with a concomitant increase in the number of cells in Sub-G1 phase, indicative of cell death. Western blotting showed LC3B and PARP cleavage, indicating 225-NP-treatment activated both autophagy- and apoptosis-mediated cell death. The 225-NP strongly induced ??H2AX and phosphorylated histone H3, markers indicative of DNA damage and mitosis, respectively. Additionally, significant ??H2AX foci formation was observed in 225-NP-treated cells compared with control treatment groups, suggesting 225-NP induced cell death by triggering DNA damage. The 225-NP-mediated DNA damage involved abrogation of the G2/M checkpoint by inhibiting BRCA1, Chk1, and phospho-Cdc2/CDK1 protein expression. In vivo therapy studies showed 225-NP treatment reduced EGFR phosphorylation, increased ??H2AX foci, and induced tumor cell apoptosis, resulting in suppression of tumor growth.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The 225-NP treatment induces DNA damage and abrogates G2/M phase of the cell cycle, leading to cellular apoptosis and suppression of lung tumor growth both in vitro and in vivo. Our findings provide a rationale for combining 225-NP with other DNA-damaging agents for achieving enhanced anticancer activity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kuroda</LastName>
                    <ForeName>Shinji</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tam</LastName>
                    <ForeName>Justina</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roth</LastName>
                    <ForeName>Jack A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sokolov</LastName>
                    <ForeName>Konstantin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramesh</LastName>
                    <ForeName>Rajagopal</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA ; Graduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA ; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P50CA070907</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA103830</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R03EB009182</GrantID>
                    <Acronym>EB</Acronym>
                    <Agency>NIBIB NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Int J Nanomedicine</MedlineTA>
            <NlmUniqueID>101263847</NlmUniqueID>
            <ISSNLinking>1176-9114</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">autophagy</Keyword>
            <Keyword MajorTopicYN="N">epidermal growth factor receptor</Keyword>
            <Keyword MajorTopicYN="N">lung cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S65990</ArticleId>
            <ArticleId IdType="pii">ijn-9-3825</ArticleId>
            <ArticleId IdType="pubmed">25143731</ArticleId>
            <ArticleId IdType="pmc">PMC4134185</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25143665</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1875-8630</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Disease markers</Title>
                <ISOAbbreviation>Dis. Markers</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recipients with in utero induction of tolerance upregulated MHC class I in the engrafted donor skin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>531092</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/531092</ELocationID>
            <Abstract>
                <AbstractText>The alterations in MHC class I expression play a crucial step in immune evasion of cancer or virus-infected cells. This study aimed to examine whether tolerized grafts modified MHC class I expression. FVB/N mice were rendered tolerant of C57BL/6 alloantigens by in utero transplantation of C57BL/6 marrows. Postnatally, engrafted donor skins and leukocytes were examined for their MHC expression by quantitative real-time PCR and flow cytometry. Engrafted donor skins upregulated their MHC class I related gene transcripts after short-term (1~2 weeks) or long-term (&gt;1 month) engraftment. This biological phenomenon was simultaneously associated with upregulation of TAP1 gene transcripts, suggesting an important role of TAP1 in the regulation of MHC class I pathway. The surface MHC class I molecules of H-2K(b) in engrafted donor leukocytes consistently showed overexpression. Conclusively, the induction of allograft tolerance involved biological modifications of donor transplants. The overexpression of MHC class I within engrafted transplants of tolerant mice might be used as the tolerance biomarkers for identifying a state of graft tolerance.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jeng-Chang</ForeName>
                    <Initials>JC</Initials>
                    <Identifier Source="ORCID">0000-0002-7776-4338</Identifier>
                    <Affiliation>Department of Surgery, Chang Gung Children's Hospital, College of Medicine, Chang Gung University, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ou</LastName>
                    <ForeName>Liang-Shiou</ForeName>
                    <Initials>LS</Initials>
                    <Affiliation>Department of Allergy, Asthma and Rheumatology, Chang Gung Children's Hospital, College of Medicine, Chang Gung University, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Hsiu-Yueh</ForeName>
                    <Initials>HY</Initials>
                    <Affiliation>Pediatric Research Center, Chang Gung Children's Hospital, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuo</LastName>
                    <ForeName>Ming-Ling</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, 259 Wen-Hwa 1st Road, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Pei-Yeh</ForeName>
                    <Initials>PY</Initials>
                    <Affiliation>Department of Surgery, Chang Gung Children's Hospital, College of Medicine, Chang Gung University, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Hsueh-Ling</ForeName>
                    <Initials>HL</Initials>
                    <Affiliation>Pediatric Research Center, Chang Gung Children's Hospital, 5 Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Dis Markers</MedlineTA>
            <NlmUniqueID>8604127</NlmUniqueID>
            <ISSNLinking>0278-0240</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/531092</ArticleId>
            <ArticleId IdType="pubmed">25143665</ArticleId>
            <ArticleId IdType="pmc">PMC4131087</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143632</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1479-6805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of endocrinology</Title>
                <ISOAbbreviation>J. Endocrinol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>20 YEARS OF LEPTIN: What we know and what the future holds.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JOE-14-0506</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">This special issue of the Journal of Endocrinology celebrates the twentieth anniversary of the discovery of leptin, a hormone produced by adipose tissue which provides critical signals to the organism regarding the status of its energy stores. The discovery of leptin not only revolutionised our understanding of endocrine physiology but has also resulted in a registered medicinal product which is already improving the health of patients with serious metabolic diseases. In this issue we have gathered together a group of essays by some of the world leaders in leptin research, including an overview by Dr Jeffrey Friedman who, in his seminal article in December 1994, described the adipocyte-derived hormone, the lack of which was responsible for the severe obesity of ob/ob mice and suggested that it be named leptin.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>O'Rahilly</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>S O'Rahilly, University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Universty of Cambridge, Cambridge , United Kingdom so104@medschl.cam.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Endocrinol</MedlineTA>
            <NlmUniqueID>0375363</NlmUniqueID>
            <ISSNLinking>0022-0795</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JOE-14-0506</ArticleId>
            <ArticleId IdType="doi">10.1530/JOE-14-0506</ArticleId>
            <ArticleId IdType="pubmed">25143632</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143627</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Activation of TRPML1 Clears Intraneuronal A?? in Preclinical Models of HIV Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11485-503</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0210-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Antiretroviral therapy extends the lifespan of human immunodeficiency virus (HIV)-infected patients, but many survivors develop premature impairments in cognition. These residual cognitive impairments may involve aberrant deposition of amyloid ??-peptides (A??). By unknown mechanisms, A?? accumulates in the lysosomal and autophagic compartments of neurons in the HIV-infected brain. Here we identify the molecular events evoked by the HIV coat protein gp120 that facilitate the intraneuronal accumulation of A??. We created a triple transgenic gp120/APP/PS1 mouse that recapitulates intraneuronal deposition of A?? in a manner reminiscent of the HIV-infected brain. In cultured neurons, we found that the HIV coat protein gp120 increased the transcriptional expression of BACE1 through repression of PPAR??, and increased APP expression by promoting interaction of the translation-activating RBP heterogeneous nuclear ribonucleoprotein C with APP mRNA. APP and BACE1 were colocalized into stabilized membrane microdomains, where the ??-cleavage of APP and A?? formation were enhanced. A??-peptides became localized to lysosomes that were engorged with sphingomyelin and calcium. Stimulating calcium efflux from lysosomes with a TRPM1 agonist promoted calcium efflux, luminal acidification, and cleared both sphingomyelin and A?? from lysosomes. These findings suggest that therapeutics targeted to reduce lysosomal pH in neurodegenerative conditions may protect neurons by facilitating the clearance of accumulated sphingolipids and A??-peptides.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411485-19$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>Mihyun</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Johns Hopkins University School of Medicine, Department of Neurology, Division of Neuroimmunology and Neurological Infections, Baltimore, Maryland 21287.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Neha</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Johns Hopkins University School of Medicine, Department of Neurology, Division of Neuroimmunology and Neurological Infections, Baltimore, Maryland 21287.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Haoxing</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Mingwaoh</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Section of Infections of the Nervous Systems, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tominaga-Yamanaka</LastName>
                    <ForeName>Kumiko</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratories of Genetics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nath</LastName>
                    <ForeName>Avindra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Section of Infections of the Nervous Systems, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geiger</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, North Dakota 58202-9037, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gorospe</LastName>
                    <ForeName>Myriam</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Laboratories of Genetics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mattson</LastName>
                    <ForeName>Mark P</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>Neurosciences, National Institute on Aging-IRP, National Institutes of Health, Baltimore, Maryland 21224-6825.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haughey</LastName>
                    <ForeName>Norman J</ForeName>
                    <Initials>NJ</Initials>
                    <Affiliation>Johns Hopkins University School of Medicine, Department of Neurology, Division of Neuroimmunology and Neurological Infections, Baltimore, Maryland 21287, nhaughe1@jhmi.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HIV</Keyword>
            <Keyword MajorTopicYN="N">amyloid</Keyword>
            <Keyword MajorTopicYN="N">dementia</Keyword>
            <Keyword MajorTopicYN="N">endosome</Keyword>
            <Keyword MajorTopicYN="N">lysosome</Keyword>
            <Keyword MajorTopicYN="N">neuron</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11485</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0210-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143627</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143625</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Threonine 149 Phosphorylation Enhances ??FosB Transcriptional Activity to Control Psychomotor Responses to Cocaine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11461-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1611-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Stable changes in neuronal gene expression have been studied as mediators of addicted states. Of particular interest is the transcription factor ??FosB, a truncated and stable FosB gene product whose expression in nucleus accumbens (NAc), a key reward region, is induced by chronic exposure to virtually all drugs of abuse and regulates their psychomotor and rewarding effects. Phosphorylation at Ser(27) contributes to ??FosB's stability and accumulation following repeated exposure to drugs, and our recent work demonstrates that the protein kinase CaMKII?? phosphorylates ??FosB at Ser(27) and regulates its stability in vivo. Here, we identify two additional sites on ??FosB that are phosphorylated in vitro by CaMKII??, Thr(149) and Thr(180), and demonstrate their regulation in vivo by chronic cocaine. We show that phosphomimetic mutation of Thr(149) (T149D) dramatically increases AP-1 transcriptional activity while alanine mutation does not affect transcriptional activity when compared with wild-type (WT) ??FosB. Using in vivo viral-mediated gene transfer of ??FosB-T149D or ??FosB-T149A in mouse NAc, we determined that overexpression of ??FosB-T149D in NAc leads to greater locomotor activity in response to an initial low dose of cocaine than does WT ??FosB, while overexpression of ??FosB-T149A does not produce the psychomotor sensitization to chronic low-dose cocaine seen after overexpression of WT ??FosB and abrogates the sensitization seen in control animals at higher cocaine doses. We further demonstrate that mutation of Thr(149) does not affect the stability of ??FosB overexpressed in mouse NAc, suggesting that the behavioral effects of these mutations are driven by their altered transcriptional properties.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411461-09$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cates</LastName>
                    <ForeName>Hannah M</ForeName>
                    <Initials>HM</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thibault</LastName>
                    <ForeName>Mackenzie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pfau</LastName>
                    <ForeName>Madeline</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heller</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2984-8705</Identifier>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eagle</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7879-5996</Identifier>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gajewski</LastName>
                    <ForeName>Paula</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bagot</LastName>
                    <ForeName>Rosemary</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colangelo</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Molecular Biophysics and Biochemistry/Keck Biotechnology Services, New Haven, Connecticut 06511, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abbott</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Molecular Biophysics and Biochemistry/Keck Biotechnology Services, New Haven, Connecticut 06511, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rudenko</LastName>
                    <ForeName>Gabby</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Pharmacology/Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, Texas 77555.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neve</LastName>
                    <ForeName>Rachael</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nestler</LastName>
                    <ForeName>Eric J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robison</LastName>
                    <ForeName>Alfred J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Department of Physiology, Michigan State University, Lansing, Michigan 48824, robiso45@msu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CaMKII</Keyword>
            <Keyword MajorTopicYN="N">accumbens</Keyword>
            <Keyword MajorTopicYN="N">cocaine</Keyword>
            <Keyword MajorTopicYN="N">phosphorylation</Keyword>
            <Keyword MajorTopicYN="N">transcription</Keyword>
            <Keyword MajorTopicYN="N">??FosB</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11461</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1611-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143625</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143621</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Amyloid-??-Induced Action Potential Desynchronization and Degradation of Hippocampal Gamma Oscillations Is Prevented by Interference with Peptide Conformation Change and Aggregation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11416-25</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1195-14.2014</ELocationID>
            <Abstract>
                <AbstractText>The amyloid-?? hypothesis of Alzheimer's Disease (AD) focuses on accumulation of amyloid-?? peptide (A??) as the main culprit for the myriad physiological changes seen during development and progression of AD including desynchronization of neuronal action potentials, consequent development of aberrant brain rhythms relevant for cognition, and final emergence of cognitive deficits. The aim of this study was to elucidate the cellular and synaptic mechanisms underlying the A??-induced degradation of gamma oscillations in AD, to identify aggregation state(s) of A?? that mediate the peptides neurotoxicity, and to test ways to prevent the neurotoxic A?? effect. We show that A??1-42 in physiological concentrations acutely degrades mouse hippocampal gamma oscillations in a concentration- and time-dependent manner. The underlying cause is an A??-induced desynchronization of action potential generation in pyramidal cells and a shift of the excitatory/inhibitory equilibrium in the hippocampal network. Using purified preparations containing different aggregation states of A??, as well as a designed ligand and a BRICHOS chaperone domain, we provide evidence that the severity of A?? neurotoxicity increases with increasing concentration of fibrillar over monomeric A?? forms, and that A??-induced degradation of gamma oscillations and excitatory/inhibitory equilibrium is prevented by compounds that interfere with A?? aggregation. Our study provides correlative evidence for a link between A??-induced effects on synaptic currents and AD-relevant neuronal network oscillations, identifies the responsible aggregation state of A?? and proofs that strategies preventing peptide aggregation are able to prevent the deleterious action of A?? on the excitatory/inhibitory equilibrium and on the gamma rhythm.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411416-10$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kurudenkandy</LastName>
                    <ForeName>Firoz Roshan</ForeName>
                    <Initials>FR</Initials>
                    <Affiliation>Neuronal Oscillations Laboratory, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zilberter</LastName>
                    <ForeName>Misha</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Neuronal Oscillations Laboratory, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biverst??l</LastName>
                    <ForeName>Henrik</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Presto</LastName>
                    <ForeName>Jenny</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honcharenko</LastName>
                    <ForeName>Dmytro</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Biosciences and Nutrition, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Str??mberg</LastName>
                    <ForeName>Roger</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Biosciences and Nutrition, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johansson</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, The Biomedical Centre, 75123 Uppsala, Sweden, and Institute of Mathematics and Natural Sciences, Tallinn University, 10120 Tallinn, Estonia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winblad</LastName>
                    <ForeName>Bengt</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fisahn</LastName>
                    <ForeName>Andr??</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Neuronal Oscillations Laboratory, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, and andre.fisahn@ki.se.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
            <Keyword MajorTopicYN="N">BRICHOS domain</Keyword>
            <Keyword MajorTopicYN="N">amyloid-?? peptide</Keyword>
            <Keyword MajorTopicYN="N">gamma oscillations</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">neuronal synchronization</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11416</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1195-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143621</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143620</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leptin Acts via Lateral Hypothalamic Area Neurotensin Neurons to Inhibit Orexin Neurons by Multiple GABA-Independent Mechanisms.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11405-15</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5167-13.2014</ELocationID>
            <Abstract>
                <AbstractText>The adipocyte-derived hormone leptin modulates neural systems appropriately for the status of body energy stores. Leptin inhibits lateral hypothalamic area (LHA) orexin (OX; also known as hypocretin)-producing neurons, which control feeding, activity, and energy expenditure, among other parameters. Our previous results suggest that GABAergic LHA leptin receptor (LepRb)-containing and neurotensin (Nts)-containing (LepRb(Nts)) neurons lie in close apposition with OX neurons and control Ox mRNA expression. Here, we show that, similar to leptin, activation of LHA Nts neurons by the excitatory hM3Dq DREADD (designer receptor exclusively activated by designer drugs) hyperpolarizes membrane potential and suppresses action potential firing in OX neurons in mouse hypothalamic slices. Furthermore, ablation of LepRb from Nts neurons abrogated the leptin-mediated inhibition, demonstrating that LepRb(Nts) neurons mediate the inhibition of OX neurons by leptin. Leptin did not significantly enhance GABAA-mediated inhibitory synaptic transmission, and GABA receptor antagonists did not block leptin-mediated inhibition of OX neuron activity. Rather, leptin diminished the frequency of spontaneous EPSCs onto OX neurons. Furthermore, leptin indirectly activated an ATP-sensitive potassium (KATP) channel in OX neurons, which was required for the hyperpolarization of OX neurons by leptin. Although Nts did not alter OX activity, galanin, which is coexpressed in LepRb(Nts) neurons, inhibited OX neurons, whereas the galanin receptor antagonist M40 (galanin-(1-12)-Pro3-(Ala-Leu)2-Ala amide) prevented the leptin-induced hyperpolarization of OX cells. These findings demonstrate that leptin indirectly inhibits OX neurons by acting on LHA LepRb(Nts) neurons to mediate two distinct GABA-independent mechanisms of inhibition: the presynaptic inhibition of excitatory neurotransmission and the opening of KATP channels.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411405-11$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Goforth</LastName>
                    <ForeName>Paulette B</ForeName>
                    <Initials>PB</Initials>
                    <Affiliation>Departments of Pharmacology and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leinninger</LastName>
                    <ForeName>Gina M</ForeName>
                    <Initials>GM</Initials>
                    <Affiliation>Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, and Department of Physiology, Michigan State University, East Lansing, Michigan 48824.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patterson</LastName>
                    <ForeName>Christa M</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Satin</LastName>
                    <ForeName>Leslie S</ForeName>
                    <Initials>LS</Initials>
                    <Affiliation>Departments of Pharmacology and mgmyers@umich.edu lsatin@umich.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Myers</LastName>
                    <ForeName>Martin G</ForeName>
                    <Initials>MG</Initials>
                    <Suffix>Jr</Suffix>
                    <Affiliation>Molecular and Integrative Physiology, and Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, and mgmyers@umich.edu lsatin@umich.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EPSC</Keyword>
            <Keyword MajorTopicYN="N">GABA</Keyword>
            <Keyword MajorTopicYN="N">LHA</Keyword>
            <Keyword MajorTopicYN="N">leptin</Keyword>
            <Keyword MajorTopicYN="N">neurotensin</Keyword>
            <Keyword MajorTopicYN="N">orexin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11405</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5167-13.2014</ArticleId>
            <ArticleId IdType="pubmed">25143620</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143618</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanisms of sharp wave initiation and ripple generation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11385-98</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0867-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Replay of neuronal activity during hippocampal sharp wave-ripples (SWRs) is essential in memory formation. To understand the mechanisms underlying the initiation of irregularly occurring SWRs and the generation of periodic ripples, we selectively manipulated different components of the CA3 network in mouse hippocampal slices. We recorded EPSCs and IPSCs to examine the buildup of neuronal activity preceding SWRs and analyzed the distribution of time intervals between subsequent SWR events. Our results suggest that SWRs are initiated through a combined refractory and stochastic mechanism. SWRs initiate when firing in a set of spontaneously active pyramidal cells triggers a gradual, exponential buildup of activity in the recurrent CA3 network. We showed that this tonic excitatory envelope drives reciprocally connected parvalbumin-positive basket cells, which start ripple-frequency spiking that is phase-locked through reciprocal inhibition. The synchronized GABAA receptor-mediated currents give rise to a major component of the ripple-frequency oscillation in the local field potential and organize the phase-locked spiking of pyramidal cells. Optogenetic stimulation of parvalbumin-positive cells evoked full SWRs and EPSC sequences in pyramidal cells. Even with excitation blocked, tonic driving of parvalbumin-positive cells evoked ripple oscillations. Conversely, optogenetic silencing of parvalbumin-positive cells interrupted the SWRs or inhibited their occurrence. Local drug applications and modeling experiments confirmed that the activity of parvalbumin-positive perisomatic inhibitory neurons is both necessary and sufficient for ripple-frequency current and rhythm generation. These interneurons are thus essential in organizing pyramidal cell activity not only during gamma oscillation, but, in a different configuration, during SWRs.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411385-14$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schlingloff</LastName>
                    <ForeName>D??niel</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, J??nos Szent??gothai PhD Program of Semmelweis University, H-1085 Budapest, Hungary.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>K??li</LastName>
                    <ForeName>Szabolcs</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2740-6057</Identifier>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, Faculty of Information Technology, P??zm??ny P??ter Catholic University, H-1083 Budapest, Hungary, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Freund</LastName>
                    <ForeName>Tam??s F</ForeName>
                    <Initials>TF</Initials>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, Faculty of Information Technology, P??zm??ny P??ter Catholic University, H-1083 Budapest, Hungary, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>H??jos</LastName>
                    <ForeName>Norbert</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guly??s</LastName>
                    <ForeName>Attila I</ForeName>
                    <Initials>AI</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4961-636X</Identifier>
                    <Affiliation>Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1083 Budapest, Hungary, gulyas@koki.hu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">basket cell</Keyword>
            <Keyword MajorTopicYN="N">current generator</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">inhibition</Keyword>
            <Keyword MajorTopicYN="N">oscillation</Keyword>
            <Keyword MajorTopicYN="N">rhythm</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11385</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0867-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143618</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143617</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of the dorsal medial habenula in the regulation of voluntary activity, motor function, hedonic state, and primary reinforcement.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11366-84</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1861-14.2014</ELocationID>
            <Abstract>
                <AbstractText>The habenular complex in the epithalamus consists of distinct regions with diverse neuronal populations. Past studies have suggested a role for the habenula in voluntary exercise motivation and reinforcement of intracranial self-stimulation but have not assigned these effects to specific habenula subnuclei. Here, we have developed a genetic model in which neurons of the dorsal medial habenula (dMHb) are developmentally eliminated, via tissue-specific deletion of the transcription factor Pou4f1 (Brn3a). Mice with dMHb lesions perform poorly in motivation-based locomotor behaviors, such as voluntary wheel running and the accelerating rotarod, but show only minor abnormalities in gait and balance and exhibit normal levels of basal locomotion. These mice also show deficits in sucrose preference, but not in the forced swim test, two measures of depression-related phenotypes in rodents. We have also used Cre recombinase-mediated expression of channelrhodopsin-2 and halorhodopsin to activate dMHb neurons or silence their output in freely moving mice, respectively. Optical activation of the dMHb in vivo supports intracranial self-stimulation, showing that dMHb activity is intrinsically reinforcing, whereas optical silencing of dMHb outputs is aversive. Together, our findings demonstrate that the dMHb is involved in exercise motivation and the regulation of hedonic state, and is part of an intrinsic reinforcement circuit.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411366-19$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Yun-Wei A</ForeName>
                    <Initials>YW</Initials>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Si D</ForeName>
                    <Initials>SD</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8251-1450</Identifier>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Shirong</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Sanford-Burnham Medical Research Institute, La Jolla, California 92037.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morton</LastName>
                    <ForeName>Glenn</ForeName>
                    <Initials>G</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4823-3116</Identifier>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zariwala</LastName>
                    <ForeName>Hatim A</ForeName>
                    <Initials>HA</Initials>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de la Iglesia</LastName>
                    <ForeName>Horacio O</ForeName>
                    <Initials>HO</Initials>
                    <Affiliation>Department of Biology, University of Washington, Seattle, Washington 98195-1800.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Turner</LastName>
                    <ForeName>Eric E</ForeName>
                    <Initials>EE</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5499-6788</Identifier>
                    <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington 98101, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, and Center on Human Development and Disability, University of Washington, Seattle, Washington 98195 eric.turner@seattlechildrens.org.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">exercise motivation</Keyword>
            <Keyword MajorTopicYN="N">interpeduncular nucleus</Keyword>
            <Keyword MajorTopicYN="N">intracranial self-stimulation</Keyword>
            <Keyword MajorTopicYN="N">medial habenula</Keyword>
            <Keyword MajorTopicYN="N">optogenetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11366</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1861-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143617</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143608</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neural Cell Adhesion Molecule NrCAM Regulates Semaphorin 3F-Induced Dendritic Spine Remodeling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11274-87</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1774-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Neuron-glial related cell adhesion molecule (NrCAM) is a regulator of axon growth and repellent guidance, and has been implicated in autism spectrum disorders. Here a novel postsynaptic role for NrCAM in Semaphorin3F (Sema3F)-induced dendritic spine remodeling was identified in pyramidal neurons of the primary visual cortex (V1). NrCAM localized to dendritic spines of star pyramidal cells in postnatal V1, where it was coexpressed with Sema3F. NrCAM deletion in mice resulted in elevated spine densities on apical dendrites of star pyramidal cells at both postnatal and adult stages, and electron microscopy revealed increased numbers of asymmetric synapses in layer 4 of V1. Whole-cell recordings in cortical slices from NrCAM-null mice revealed increased frequency of mEPSCs in star pyramidal neurons. Recombinant Sema3F-Fc protein induced spine retraction on apical dendrites of wild-type, but not NrCAM-null cortical neurons in culture, while re-expression of NrCAM rescued the spine retraction response. NrCAM formed a complex in brain with Sema3F receptor subunits Neuropilin-2 (Npn-2) and PlexinA3 (PlexA3) through an Npn-2-binding sequence (TARNER) in the extracellular Ig1 domain. A trans heterozygous genetic interaction test demonstrated that Sema3F and NrCAM pathways interacted in vivo to regulate spine density in star pyramidal neurons. These findings reveal NrCAM as a novel postnatal regulator of dendritic spine density in cortical pyramidal neurons, and an integral component of the Sema3F receptor complex. The results implicate NrCAM as a contributor to excitatory/inhibitory balance in neocortical circuits.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411274-14$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Demyanenko</LastName>
                    <ForeName>Galina P</ForeName>
                    <Initials>GP</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohan</LastName>
                    <ForeName>Vishwa</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xuying</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brennaman</LastName>
                    <ForeName>Leann H</ForeName>
                    <Initials>LH</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dharbal</LastName>
                    <ForeName>Katherine E S</ForeName>
                    <Initials>KE</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tran</LastName>
                    <ForeName>Tracy S</ForeName>
                    <Initials>TS</Initials>
                    <Affiliation>Department of Biological Sciences, Rutgers University, Newark, New Jersey 07102.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manis</LastName>
                    <ForeName>Paul B</ForeName>
                    <Initials>PB</Initials>
                    <Affiliation>Departments of Otolaryngology/Head and Neck Surgery and Cell and Molecular Physiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maness</LastName>
                    <ForeName>Patricia F</ForeName>
                    <Initials>PF</Initials>
                    <Affiliation>Departments of Biochemistry and Biophysics and srclab@med.unc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">NrCAM</Keyword>
            <Keyword MajorTopicYN="N">cell adhesion</Keyword>
            <Keyword MajorTopicYN="N">cortical pyramidal neurons</Keyword>
            <Keyword MajorTopicYN="N">semaphorin</Keyword>
            <Keyword MajorTopicYN="N">spine morphogenesis</Keyword>
            <Keyword MajorTopicYN="N">visual cortex</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11274</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1774-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143608</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143604</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Astroglial connexin43 hemichannels tune Basal excitatory synaptic transmission.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11228-32</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0015-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Fast exchange of extracellular signals between neurons and astrocytes is crucial for synaptic function. Over the last few decades, different pathways of astroglial release of neuroactive substances have been proposed to modulate neurotransmission. However, their involvement in physiological conditions is highly debated. Connexins, the gap junction forming proteins, are highly expressed in astrocytes and have recently been shown to scale synaptic transmission and plasticity. Interestingly, in addition to gap junction channels, the most abundant connexin (Cx) in astrocytes, Cx43, also forms hemichannels. While such channels are mostly active in pathological conditions, they have recently been shown to regulate cognitive function. However, whether astroglial Cx43 hemichannels are active in resting conditions and regulate basal synaptic transmission is unknown. Here we show that in basal conditions Cx43 forms functional hemichannels in astrocytes from mouse hippocampal slices. We furthermore demonstrate that the activity of astroglial Cx43 hemichannels in resting states regulates basal excitatory synaptic transmission of hippocampal CA1 pyramidal cells through ATP signaling. These data reveal Cx43 hemichannels as a novel astroglial release pathway at play in basal conditions, which tunes the moment-to-moment glutamatergic synaptic transmission.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411228-05$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chever</LastName>
                    <ForeName>Oana</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Coll??ge de France, Centre National de la Recherche Scientifique, Unit?? Mixte de Recherche 7241, Institut National de la Sant?? et de la Recherche M??dicale U1050, 75005 Paris, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Chun-Yao</ForeName>
                    <Initials>CY</Initials>
                    <Affiliation>Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Coll??ge de France, Centre National de la Recherche Scientifique, Unit?? Mixte de Recherche 7241, Institut National de la Sant?? et de la Recherche M??dicale U1050, 75005 Paris, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rouach</LastName>
                    <ForeName>Nathalie</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Coll??ge de France, Centre National de la Recherche Scientifique, Unit?? Mixte de Recherche 7241, Institut National de la Sant?? et de la Recherche M??dicale U1050, 75005 Paris, France nathalie.rouach@college-de-france.fr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">astrocytes</Keyword>
            <Keyword MajorTopicYN="N">basal synaptic transmission</Keyword>
            <Keyword MajorTopicYN="N">connexin43</Keyword>
            <Keyword MajorTopicYN="N">hemichannel</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">physiology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11228</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0015-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143604</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143602</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chromophore supply rate-limits Mammalian photoreceptor dark adaptation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11212-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1245-14.2014</ELocationID>
            <Abstract>
                <AbstractText>Efficient regeneration of visual pigment following its destruction by light is critical for the function of mammalian photoreceptors. Here, we show that misexpression of a subset of cone genes in the rd7 mouse hybrid rods enables them to access the normally cone-specific retina visual cycle. The rapid supply of chromophore by the retina visual cycle dramatically accelerated the mouse rod dark adaptation. At the same time, the competition between rods and cones for retina-derived chromophore slowed cone dark adaptation, indicating that the cone specificity of the retina visual cycle is key for rapid cone dark adaptation. Our findings demonstrate that mammalian photoreceptor dark adaptation is dominated by the supply of chromophore. Misexpression of cone genes in rods may represent a novel approach to treating visual disorders associated with mutations of visual cycle proteins or with reduced retinal pigment epithelium function due to aging.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411212-10$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jin-Shan</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Departments of Ophthalmology and Visual Sciences and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nymark</LastName>
                    <ForeName>Soile</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, Department of Electronics and Communications Engineering, Tampere University of Technology and BioMediTech, FI-33014 Tampere, Finland, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frederiksen</LastName>
                    <ForeName>Rikard</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Estevez</LastName>
                    <ForeName>Maureen E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, Department of Neuroscience, Brown University, Providence, Rhode Island 02912.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Susan Q</ForeName>
                    <Initials>SQ</Initials>
                    <Affiliation>Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corbo</LastName>
                    <ForeName>Joseph C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cornwall</LastName>
                    <ForeName>M Carter</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Departments of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kefalov</LastName>
                    <ForeName>Vladimir J</ForeName>
                    <Initials>VJ</Initials>
                    <Affiliation>Departments of Ophthalmology and Visual Sciences and kefalov@wustl.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">dark adaptation</Keyword>
            <Keyword MajorTopicYN="N">photoreceptors</Keyword>
            <Keyword MajorTopicYN="N">pigment regeneration</Keyword>
            <Keyword MajorTopicYN="N">retina</Keyword>
            <Keyword MajorTopicYN="N">retinol dehydrogenase</Keyword>
            <Keyword MajorTopicYN="N">visual cycle</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11212</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1245-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143602</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25143599</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Temporal and Region-Specific Requirements of ??CaMKII in Spatial and Contextual Learning.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11180-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0640-14.2014</ELocationID>
            <Abstract>
                <AbstractText>The ?? isoform of the calcium/calmodulin-dependent protein kinase II (??CaMKII) has been implicated extensively in molecular and cellular mechanisms underlying spatial and contextual learning in a wide variety of species. Germline deletion of Camk2a leads to severe deficits in spatial and contextual learning in mice. However, the temporal and region-specific requirements for ??CaMKII have remained largely unexplored. Here, we generated conditional Camk2a mutants to examine the influence of spatially restricted and temporally controlled expression of ??CaMKII. Forebrain-specific deletion of the Camk2a gene resulted in severe deficits in water maze and contextual fear learning, whereas mice with deletion restricted to the cerebellum learned normally. Furthermore, we found that temporally controlled deletion of the Camk2a gene in adult mice is as detrimental as germline deletion for learning and synaptic plasticity. Together, we confirm the requirement for ??CaMKII in the forebrain, but not the cerebellum, in spatial and contextual learning. Moreover, we highlight the absolute requirement for intact ??CaMKII expression at the time of learning.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 the authors 0270-6474/14/3411180-08$15.00/0.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Achterberg</LastName>
                    <ForeName>Katharina G</ForeName>
                    <Initials>KG</Initials>
                    <Affiliation>Department of Psychiatry.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buitendijk</LastName>
                    <ForeName>Gabri??lle H S</ForeName>
                    <Initials>GH</Initials>
                    <Affiliation>Department of Neuroscience, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kool</LastName>
                    <ForeName>Martijn J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goorden</LastName>
                    <ForeName>Susanna M I</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Post</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Neuroscience, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slump</LastName>
                    <ForeName>Denise E</ForeName>
                    <Initials>DE</Initials>
                    <Affiliation>Department of Psychiatry.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Alcino J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Departments of Neurobiology, Psychiatry, Psychology, and Brain Research Institute, University of California, Los Angeles, California 90095.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Woerden</LastName>
                    <ForeName>Geeske M</ForeName>
                    <Initials>GM</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kushner</LastName>
                    <ForeName>Steven A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Department of Psychiatry, s.kushner@erasmusmc.nl y.elgersma@erasmusmc.nl.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elgersma</LastName>
                    <ForeName>Ype</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Neuroscience, and ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, 3015 GE, Rotterdam, The Netherlands, and s.kushner@erasmusmc.nl y.elgersma@erasmusmc.nl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CaMKII</Keyword>
            <Keyword MajorTopicYN="N">cerebellum</Keyword>
            <Keyword MajorTopicYN="N">fear conditioning</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">learning</Keyword>
            <Keyword MajorTopicYN="N">spatial learning</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">34/34/11180</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0640-14.2014</ArticleId>
            <ArticleId IdType="pubmed">25143599</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143588</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1091-6490</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Primary cilia signaling mediates intraocular pressure sensation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">201323292</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Lowe syndrome is a rare X-linked congenital disease that presents with congenital cataracts and glaucoma, as well as renal and cerebral dysfunction. OCRL, an inositol polyphosphate 5-phosphatase, is mutated in Lowe syndrome. We previously showed that OCRL is involved in vesicular trafficking to the primary cilium. Primary cilia are sensory organelles on the surface of eukaryotic cells that mediate mechanotransduction in the kidney, brain, and bone. However, their potential role in the trabecular meshwork (TM) in the eye, which regulates intraocular pressure, is unknown. Here, we show that TM cells, which are defective in glaucoma, have primary cilia that are critical for response to pressure changes. Primary cilia in TM cells shorten in response to fluid flow and elevated hydrostatic pressure, and promote increased transcription of TNF-??, TGF-??, and GLI1 genes. Furthermore, OCRL is found to be required for primary cilia to respond to pressure stimulation. The interaction of OCRL with transient receptor potential vanilloid 4 (TRPV4), a ciliary mechanosensory channel, suggests that OCRL may act through regulation of this channel. A novel disease-causing OCRL allele prevents TRPV4-mediated calcium signaling. In addition, TRPV4 agonist GSK 1016790A treatment reduced intraocular pressure in mice; TRPV4 knockout animals exhibited elevated intraocular pressure and shortened cilia. Thus, mechanotransduction by primary cilia in TM cells is implicated in how the eye senses pressure changes and highlights OCRL and TRPV4 as attractive therapeutic targets for the treatment of glaucoma. Implications of OCRL and TRPV4 in primary cilia function may also shed light on mechanosensation in other organ systems.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Na</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8046-9372</Identifier>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Conwell</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xingjuan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Cellular and Integrative Physiology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kettenhofen</LastName>
                    <ForeName>Christine Insinna</ForeName>
                    <Initials>CI</Initials>
                    <Affiliation>Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201;</Affiliation>
                </Author>
                <Author>
                    <LastName>Westlake</LastName>
                    <ForeName>Christopher J</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201;</Affiliation>
                </Author>
                <Author>
                    <LastName>Cantor</LastName>
                    <ForeName>Louis B</ForeName>
                    <Initials>LB</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wells</LastName>
                    <ForeName>Clark D</ForeName>
                    <Initials>CD</Initials>
                    <Affiliation>Department of Biochemistry and Molecular Biology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Weinreb</LastName>
                    <ForeName>Robert N</ForeName>
                    <Initials>RN</Initials>
                    <Affiliation>Department of Ophthalmology, University of California, San Diego, La Jolla, CA 92037;</Affiliation>
                </Author>
                <Author>
                    <LastName>Corson</LastName>
                    <ForeName>Timothy W</ForeName>
                    <Initials>TW</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology, Department of Biochemistry and Molecular Biology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Spandau</LastName>
                    <ForeName>Dan F</ForeName>
                    <Initials>DF</Initials>
                    <Affiliation>Department of Dermatology, and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Joos</LastName>
                    <ForeName>Karen M</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Vanderbilt Eye Institute, Nashville, TN 37212; and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Iomini</LastName>
                    <ForeName>Carlo</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029.</Affiliation>
                </Author>
                <Author>
                    <LastName>Obukhov</LastName>
                    <ForeName>Alexander G</ForeName>
                    <Initials>AG</Initials>
                    <Affiliation>Department of Cellular and Integrative Physiology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Ophthalmology, Department of Biochemistry and Molecular Biology, Department of Dermatology, and sunyo@iupui.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
            <NlmUniqueID>7505876</NlmUniqueID>
            <ISSNLinking>0027-8424</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1323292111</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1323292111</ArticleId>
            <ArticleId IdType="pubmed">25143588</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143538</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1598</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neurophysiology</Title>
                <ISOAbbreviation>J. Neurophysiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Flocculus Purkinje Cell Signals in Mouse Cacna1a Calcium Channel Mutants of Escalating Severity; An Investigation of the Role of Firing Irregularity in Ataxia.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jn.00129.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mutation of the Cacna1a gene for the P/Q (CaV2.1) calcium channel invariably leads to cerebellar dysfunction. The dysfunction has been attributed to disrupted rhythmicity of cerebellar Purkinje cells, but the hypothesis remains unproven. If irregular firing rates cause cerebellar dysfunction, then the irregularity and behavioral deficits should co-vary in a series of mutant strains of escalating severity. We compared firing irregularity in floccular and anterior vermis Purkinje cells in the mildly affected rocker and moderately affected tottering Cacna1a mutants, and normal C57BL/6 mice. We also measured the amplitude and timing of modulations of floccular Purkinje cell firing rate during the horizontal vestibulo-ocular reflex (VOR, 0.25-1 Hz) and the horizontal and vertical optokinetic reflex (OKR, 0.125-1 Hz). We recorded Purkinje cells selective for rotational stimulation about the vertical axis (VAPCs) and a horizontal axis (HAPCs). In the flocculus, irregularity scaled with behavioral deficit severity, but failed to do so in the vermis, challenging the irregularity hypothesis. Mutant VAPCs exhibited unusually strong modulation during VOR and OKR, the response augmentation scaling with phenotypic severity. HAPCs exhibited increased OKR modulation, but in tottering only. The data contradict prior claims that modulation amplitude is unaffected in tottering, but support the idea that attenuated compensatory eye movements in Cacna1a mutants arise from defective transfer of Purkinje cell signals to downstream circuitry, rather than attenuated synaptic transmission within the cerebellar cortex. Shifts in the relative sizes of the VAPC and HAPC populations raise the possibility that Cacna1a mutations influence the development of floccular zone architecture.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, Journal of Neurophysiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Stahl</LastName>
                    <ForeName>John S</ForeName>
                    <Initials>JS</Initials>
                    <Affiliation>Louis Stokes Cleveland Dept. of Veterans Affairs Medical Center jss6@case.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thumser</LastName>
                    <ForeName>Zachary C</ForeName>
                    <Initials>ZC</Initials>
                    <Affiliation>Louis Stokes Cleveland Dept. of Veterans Affairs Medical Center.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Neurophysiol</MedlineTA>
            <NlmUniqueID>0375404</NlmUniqueID>
            <ISSNLinking>0022-3077</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Purkinje cell</Keyword>
            <Keyword MajorTopicYN="N">ataxia</Keyword>
            <Keyword MajorTopicYN="N">flocculus</Keyword>
            <Keyword MajorTopicYN="N">optokinetic</Keyword>
            <Keyword MajorTopicYN="N">vestibulo-ocular</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jn.00129.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/jn.00129.2014</ArticleId>
            <ArticleId IdType="pubmed">25143538</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143535</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1362-4962</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nucleic acids research</Title>
                <ISOAbbreviation>Nucleic Acids Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Retinoid acid-related orphan receptor ??, ROR??, participates in diurnal transcriptional regulation of lipid metabolic genes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">gku766</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The hepatic circadian clock plays a pivotal role in regulating major aspects of energy homeostasis and lipid metabolism. In this study, we show that ROR?? robustly regulates the rhythmic expression of several lipid metabolic genes, including the insulin-induced gene 2a, Insig2a, elongation of very long chain fatty acids-like 3, Elovl3 and sterol 12??-hydroxylase, Cyp8b1, by enhancing their expression at ZT20-4. The time-dependent increase in their expression correlates with the rhythmic expression pattern of ROR??. The enhanced recruitment of ROR?? to ROREs in their promoter region, increased histone acetylation, and reporter and mutation analysis support the concept that ROR?? regulates the transcription of several lipid metabolic genes directly by binding ROREs in their promoter regulatory region. Consistent with the disrupted expression of a number of lipid metabolic genes, loss of ROR?? reduced the level of several lipids in liver and blood in a ZT-preferred manner. Particularly the whole-body bile acid pool size was considerably reduced in ROR??(-/-) mice in part through its regulation of several Cyp genes. Similar observations were made in liver-specific ROR??-deficient mice. Altogether, our study indicates that ROR?? functions as an important link between the circadian clock and the transcriptional regulation of several metabolic genes.</AbstractText>
                <CopyrightInformation>Published by Oxford University Press on behalf of Nucleic Acids Research 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Takeda</LastName>
                    <ForeName>Yukimasa</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Cell Biology Section, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kang</LastName>
                    <ForeName>Hong Soon</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Cell Biology Section, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lih</LastName>
                    <ForeName>Fred B</ForeName>
                    <Initials>FB</Initials>
                    <Affiliation>Collaborative Mass Spectrometry Group, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Hongfeng</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Medicine, Colombia University, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Blaner</LastName>
                    <ForeName>William S</ForeName>
                    <Initials>WS</Initials>
                    <Affiliation>Department of Medicine, Colombia University, New York, NY 10032, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jetten</LastName>
                    <ForeName>Anton M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Cell Biology Section, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA jetten@niehs.nih.gov.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nucleic Acids Res</MedlineTA>
            <NlmUniqueID>0411011</NlmUniqueID>
            <ISSNLinking>0305-1048</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">gku766</ArticleId>
            <ArticleId IdType="doi">10.1093/nar/gku766</ArticleId>
            <ArticleId IdType="pubmed">25143535</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143486</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2014-03-562876</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Evidence is emerging that platelets are major contributors to innate immune responses in conditions such as acute lung injury (ALI). Platelets form heterotypic aggregates with neutrophils, and we hypothesized that lipoxin mediators regulate formation of neutrophil-platelet aggregates (NPA), and that NPA significantly contribute to ALI. LPS-induced lung injury was accompanied by platelet sequestration, activation, and intra-alveolar accumulation, and NPA formation within both blood and alveolar compartments. Using lung intravital microscopy, we observed the dynamic formation of NPA during physiologic conditions, which sharply increased with ALI. Aspirin treatment significantly reduced lung platelet sequestration and activation, NPA formation, and lung injury. Aspirin treatment increased levels of aspirin-triggered lipoxin (ATL, 15-epi-LXA4) and blocking the lipoxin A4 receptor (ALX) with a peptide antagonist (Boc2) or using ALX knockouts (Fpr2/3(-/-)) reversed this protection. LPS increased NPA formation in vitro, which was reduced by ATL, and engagement of ALX by ATL on both neutrophils and platelets was necessary to prevent aggregation. In a model of transfusion-related acute lung injury (TRALI), Boc2 also reversed aspirin protection, and treatment with ATL in both LPS and TRALI models protected from ALI. We conclude that ATL regulates neutrophil-platelet aggregation, and that platelet-neutrophil interactions are a therapeutic target in lung injury.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ortiz-Mu??oz</LastName>
                    <ForeName>Guadalupe</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Mallavia</LastName>
                    <ForeName>Be??at</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Bins</LastName>
                    <ForeName>Adriaan</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands;</Affiliation>
                </Author>
                <Author>
                    <LastName>Headley</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Krummel</LastName>
                    <ForeName>Matthew F</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Looney</LastName>
                    <ForeName>Mark R</ForeName>
                    <Initials>MR</Initials>
                    <Affiliation>Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States mark.looney@ucsf.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2014-03-562876</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2014-03-562876</ArticleId>
            <ArticleId IdType="pubmed">25143486</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25143484</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0020</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Myc-induced SUMOylation is a therapeutic vulnerability for B cell lymphoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">blood-2014-06-584524</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Myc oncogenic transcription factors (c-Myc, N-Myc and L-Myc) coordinate the control of cell growth, division and metabolism. In cancer Myc overexpression is often associated with aggressive disease, which is in part due to the destruction of select targets by the ubiquitin-proteasome system, for example Skp2(SCF)-directed destruction of the Cdk inhibitior p27(Kip1). We reasoned that Myc would also regulate SUMOylation, a related means of post-translational modification of proteins, and that this circuit would play essential roles in Myc-dependent tumorigenesis. Here we report marked increases in the expression of genes that encode regulators and components of the SUMOylation machinery in mouse and human Myc-driven lymphomas, resulting in hyperSUMOylation in these tumors. Further, inhibition of SUMOylation by genetic means disables Myc-induced proliferation, triggering G2/M cell cycle arrest, polyploidy and apoptosis. Using genetically defined cell models and conditional expression systems this response was shown to be Myc-specific. Finally, in vivo loss-of-function and pharmacologic studies demonstrated that inhibition of SUMOylation provokes rapid regression of Myc-driven lymphoma. Thus, targeting SUMOylation represents an attractive therapeutic option for lymphomas with MYC involvement.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Society of Hematology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hoellein</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Fallahi</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Schoeffmann</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Steidle</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Schaub</LastName>
                    <ForeName>Franz X</ForeName>
                    <Initials>FX</Initials>
                    <Affiliation>Department of Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Rudelius</LastName>
                    <ForeName>Martina</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Pathology and Clinical Cancer Center Mainfranke, Universitaet Wuerzburg, Wuerzburg, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Laitinen</LastName>
                    <ForeName>Iina</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Nilsson</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Sweden;</Affiliation>
                </Author>
                <Author>
                    <LastName>Goga</LastName>
                    <ForeName>Andrei</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Cell/Tissue Biology, University of California, San Francisco, CA, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Peschel</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany;</Affiliation>
                </Author>
                <Author>
                    <LastName>Nilsson</LastName>
                    <ForeName>Jonas A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Sweden;</Affiliation>
                </Author>
                <Author>
                    <LastName>Cleveland</LastName>
                    <ForeName>John L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Department of Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Keller</LastName>
                    <ForeName>Ulrich</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>III. Medical Department, Technische Universitaet Muenchen, Munich, Germany; ulrich.keller@lrz.tum.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2014-06-584524</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2014-06-584524</ArticleId>
            <ArticleId IdType="pubmed">25143484</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
